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Abstract
Aims:
This study tested the hypothesis that endothelial progenitor cell (EPC) pathology 
provides a unifying explanation for the tendency to carry low birthweight babies 
and subsequent increased maternal cardiovascular risk.
Methods:
We measured maternal EPC number and function, conventional cardiovascular 
risk markers, and cord blood adiponectin in 23 small for gestational age (SGA; 
birthweight <10th centile) and 23 appropriate for gestational age (AGA; 
birthweight >10th centile) pregnancies.
Results:
Median EPC count was lower (294 vs. 367, p=0.005), and EPC migratory 
capability was reduced (migration index 0.91 vs. 1.59, p<0.001) in SGA 
compared to AGA, but there was no significant difference in EPC adhesion 
(0.221 vs. 0.284 FU, p=0.257). Maternal triglyceride levels were higher in the 
SGA group compared to the AGA group (0.98 vs. 0.78 mmol/1, p=0.006), but 
there was no significant difference in cholesterol, glucose, insulin, HbAlc, 
adiponectin or blood pressure. Median umbilical cord blood adiponectin was 
lower in the SGA group (55.2 vs. 70.4 ng/ml, p=0.033), and there was a 
significant correlation between cord blood adiponectin and birthweight (r = 
0.475, p=0.005).
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Giving birth to a SGA infant was associated with lower maternal EPC number 
and reduced migratory function in vitro. EPC pathology may explain both utero­
placental insufficiency, leading to low birthweight, and future cardiovascular 
disease in the mother. SGA infants had lower cord blood adiponectin, potentially 
representing a mechanism for future cardiovascular disease in later life of the 
infant.
Conclusions:
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Blood vessels have a vital role in delivering blood and nutrients to every cell in 
the body. In addition to acting as a conduit for blood cells, the endothelial cells 
lining these vessels act to maintain vascular haemostasis, vessel wall 
permeability, appropriate blood flow, and lumen patency. Vascular endothelial 
cells regulate blood flow and organ perfusion via the release of autocrine and 
paracrine factors, they resist thrombus formation via suppression of platelet 
adhesion and aggregation and they maintain vessel patency by promoting 
fibrinolysis. The endothelium also has anti-oxidant and anti-inflammatory 
properties, regulates leucocyte adhesion and migration, smooth muscle 
proliferation and migration [1,2].
The process of vasculogenesis, or new blood vessel formation, begins in utero 
with undifferentiated angioblasts sprouting vessels that invade developing organs 
[3]. In the adult, new blood vessel formation and repair are necessary after 
ischaemia and endothelial damage. It was previously thought that de novo 
vasculogenesis was confined to the developing fetus, and could only occur in the 
adult via pre-existing, fully differentiated endothelial cells in situ in the vessel 
wall.
Chapter 1. Introduction:
1.1 Discovery and significance of Endothelial Progenitor Cells (EPCs)
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In 1994, it was noticed that the endothelium that coats prosthetic arterial grafts 
arrived via haematogenous spread of circulating cells, rather than simply by local 
spread as was previously thought [4]. This discovery led to the concept that a 
circulating adult equivalent of the haemangioblast, an endothelial progenitor cell, 
could exist.
In 1997, Asahara et al [5] isolated CD34 positive mononuclear cells from human 
peripheral blood and cultured them on fibronectin coated plates. After 7 days in 
culture the resulting spindle shaped cells took up Dil-labelled acetylated low 
density lipoprotein (acLDL), and endothelial phenotype was confirmed by 
documenting expression of eNOS and KDR (the human homolog of VEGFR-2). 
To determine if the cultured cells were indeed putative adult haemangioblasts, 
the authors used a mouse model of hind limb ischaemia. CD34 positive or 
negative cells were injected into the ischaemic model, and on post mortem 
examination Dil-labelled cells were seen in the neovascularised hind limb. The 
cells had incorporated into the blood vessel walls, and no labelled cells were seen 
in the uninjured limb.
Asahara et al had therefore demonstrated that cells isolated from peripheral 
blood could differentiate into an endothelial phenotype in vitro, and that in vivo 
these cells were capable of selectively homing to areas of ischaemia where they 
mediate angiogenesis. Since their discovery, EPCs have been widely studied in 
many disease states, and many new methods of identification, isolation and 
indeed definition have emerged.
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1.2 Definition of EPCs
The putative EPCs first described by Asahara et al are bone-marrow derived 
stem cells that proliferate in an immature state, can be mobilised into the blood 
stream, migrate to areas of endothelial damage or new blood vessel formation 
where they differentiate into a mature endothelial cell, and contribute and 
enhance the processes of endothelial repair and new blood vessel formation.
Therefore, in the laboratory, a ‘true’ EPC should be capable o f being isolated 
from blood or bone marrow, should be capable of proliferation, should display an 
undifferentiated phenotype capable of developing into an endothelial phenotype 
in appropriate conditions, and when infused into the bloodstream it should 
incorporate into blood vessels improving endothelial function and ameliorating 
ischaemia.
The cells first described by Asahara et al possessed many of these features: they 
were isolated from the mononuclear layer of peripheral blood and expressed the 
stem cell antigen CD34. After 7 days in culture conditions favouring endothelial 
differentiation the cells expressed the endothelial markers eNOS and KDR. 
Infusion of the cells into an animal ischaemia model resulted in amelioration of 
the ischaemia and on post mortem examination the cells were detected at the site 
of neovascularisation.
Since their first description, there have been over 2000 EPC-related publications, 
but a variety of methodologies have been employed to define and measure them.
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cytometry:
1.2.1 Definition of EPCs by Flow Cytometry
Cell count by flow cytometry is based on labelling cells with antibodies directed 
against surface or intracellular antigens. Circulating EPCs are rare, and represent 
between 0.01% and 0.0001% of mononuclear cells, hence 1-2 million cells are 
generally needed to be analysed to obtain an accurate result [6]. This rarity 
imposes the use of only 2-3 surface antigens, and due to overlap with other cell 
lineages, the precise antigenic phenotype of EPCs is not known [7]. Commonly 
used markers include the stem cell antigens CD34 and CD133, and the 
endothelial antigens KDR/Flk-1 (Kinase-insert Domain Receptor in humans, and 
Fetal Liver Kinase-1 in mice, representing type 2 vascular endothelial growth 
factor receptor (VEGFR)-2, CD31, also known as platelet-endothelial cells 
adhesion molecule (PECAM)-l, and von Willebrand factor (vWf). Another 
limitation to flow cytometry is that one is basing the presumed complex function 
of a cell on a relatively simple antigenic phenotype. Despite these limitations, 
cell count by flow cytometry is rapid, sensitive, specific and reproducible, and is 
becoming an increasingly popular method of evaluating EPC number.
1.2.2 Definition of EPCs by Cell Culture
Asahara et al demonstrated that CD34+ cells and KDR+ cells give rise to 
endothelial-like cells as early as 3 days after plating onto human fibronectin in an
The two main techniques used to study EPCs are by cell culture and by flow
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endothelial medium. These cells displayed typical functional properties of 
endothelial cells, such as uptake of acetylated low density lipoproteins (AcLDL) 
and binding of Ulex lectin, in addition to the expression of other endothelial 
lineage markers (such as CD31, Tie-2, KDR).
Since then, a number of variations of this protocol have been used with for 
example different culture media, or collagen instead of fibronectin coated plates. 
The majority of these studies have used the entire mononuclear layer rather than 
CD34+ cells selected by magnetic beads. In an attempt to overcome 
contamination with mature circulating endothelial cells, some groups have used a 
pre-plating procedure, whereby after 48 hours non-adherent cells are removed, 
re-plated and maintained in culture for counting at day 7. This method produces 
cells that form distinct colonies, giving this assay the name of Endothelial Cell- 
Colony Forming Units (CFU-EC), or Endothelial Colony Forming Cells (ECFC) 
assay [8]. It is these cells that are removed and discarded in Asahara’s and our 
laboratory, yet they are still termed EPCs in other laboratories. In order to 
distinguish between the two methods, the cells derived by Asahara’s and 
Dimmeler’s [9] methods are also known as Circulating Angiogenic Cells (CAC). 
Although these two distinct sub-populations of EPCs are both involved in vessel 
formation, they have different phenotypes and functional capabilities.
CACs are a haemopoietic sub-population which have strong paracrine and 
hormonal activities, and stimulate cell migration and proliferation. The second 
sub-group, ECFCs, are highly proliferative and have more endothelial-like 
characteristics. Under the influence of CACs, they migrate to sites of vessel
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formation where they differentiate into mature endothelial cells [10]. The term 
EPC is often applied to cells from either culture method, and although both sub- 
types have different properties, both have been linked to cardiovascular disease.
A recent Austrian study measured EPCs in patients with peripheral vascular 
disease using flow cytometry (CD34+/CD133+/KDR+ events), both culture 
methods for CAC and CFU-EC, and a modified Boyden chamber to assess EPC 
migratory function [11]. The authors conducted a prospective randomised control 
trial of 40 patients with symptomatic peripheral arterial disease, measuring EPC 
number and function using the above four methods before and after supervised 
exercise training. They found that after 6 months exercise training, there were 
statistically significant increases in EPC number and migratory function as 
measured by all four methods. It is interesting that despite the different properties 
of the 2 subgroups of EPCs, and the differences in methodology between flow 
cytometry and cell culture discussed above, all three methods showed parallel 
changes after the intervention.
1.2.3 Methods used in this paper
As ex vivo analysis of blood cells by flow cytometry can only count EPCs and 
quantify the expression of a limited number of surface or intracellular antigens, 
we elected to use cell culture techniques which allow both quantitative and 
qualitative properties to be defined. The cells cultures in our laboratory are 
isolated from the mononuclear layer of peripheral blood and are initially 
monocytic in morphology. After 7 days in culture favouring endothelial
14
differentiation they display an endothelial morphology, in that they are spindle 
shaped, adherent to fibronectin, stain positive for lectin and are capable of 
internalising low density lipoprotein (LDL). They also stain positive for the 
endothelial and stem cell markers KDR and CD34. In separate experiments not 
detailed in this thesis, infusion of these cells into animal models of hind-limb 
ischaemia promotes neovascularisation. We used a modified Boyden chamber 
with VEGF as a chemo-attractant, and a fibronectin adhesion assay to assess 
EPC function.
1.3 EPCs and Cardiovascular Disease
Since the role of EPCs in neovascularisation of mouse and rabbit ischaemic 
limbs was originally described in 1997, there has been much research into the 
role of EPCs in cardiovascular disease. There is now a large body of direct and 
indirect evidence to support their role in cardiovascular disease processes.
These studies have demonstrated:
- A correlation between EPC number, endothelial function and 
cardiovascular risk factors
- Reduced number of EPCs in patients with risk factors for cardiovascular 
disease such as metabolic syndrome, diabetes and smoking
- Reduced EPC number and function in patients with critical limb 
ischaemia and coronary artery disease, and reduced EPC number is a
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significant independent predictor of poor prognosis in patients with 
established coronary artery disease
- Interventions that reduce cardiovascular risk such as exercise and weight 
loss improve EPC number and function
- Reduced EPC number and function in obesity, which both normalise after 
weight loss, and EPCs from obese subjects show a reduced angiogenic 
response when injected into an animal ischaemia model
- Reduced EPC number in conditions that increase cardiovascular risk, and 
subsequent amelioration in EPC number with medical treatment, for 
example diabetes, hypertension and sub-clinical hypothyroidism
- Statins increase EPC number and function both in vitro and in vivo
- In animal models, exogenously administered EPCs migrate to areas of 
ischaemia where they mediate neovascularisation and improve 
endothelial function
In human studies exogenous EPC infusions are beneficial in coronary and 
peripheral arterial disease
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The accumulated evidence suggests that a balance between the damaging effects 
of conventional cardiovascular risk factors and the ability of circulating EPCs to 
effect endothelial repair determines cardiovascular risk.
1.3.1 Correlation between EPCs and other cardiovascular risk markers
Hill et al [8] cultured EPCs from 45 men with various degrees of cardiovascular 
risk, but without overt cardiovascular disease. They found a strong correlation 
between EPC number and combined Framingham risk factor score (i—0.47, 
P=0.001). Measurement of flow-mediated brachial-artery reactivity also revealed 
a significant relation between endothelial function and the number of progenitor 
cells (r=0.59, P<0.001). They found that levels of circulating EPCs were actually 
a better predictor of vascular reactivity than the presence or absence of 
conventional risk factors. A P-galactosidase activity assay was used as a marker 
of cellular senescence on day 7 EPCs.
They found that a higher percentage of EPCs from patients with high 
Framingham risk scores displayed a senescent phenotype (72±15 percent of the 
cells derived from the high-risk subjects vs. 27±9 percent of the cells from the 
low-risk subjects had b-galactosidase staining (P=0.005)). The authors postulated 
that endothelial injury in the absence of sufficient circulating progenitor cells 
may affect the progression of cardiovascular disease.
Jialal et al [12] measured EPCs in subjects with and without metabolic syndrome 
using flow cytometry (CD34+ KDR+) and cell culture (CFU-EC method), and a
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modified Boyden chamber was used to measure migratory activity. Smoking, 
atherosclerosis and diabetes were exclusion criteria and Metabolic Syndrome 
was defined as having 3 out of: central obesity, hypertension, dyslipidaemia or 
hypertension.
The subjects with metabolic syndrome had significantly lower (34%, p<0.001) 
CD34+KDR+ EPCs compared with their age-matched healthy volunteers. There 
were significantly lower numbers of cultured EPCs in the metabolic syndrome 
group (48%, p<0.001). There was also reduction in migratory capacity, but this 
difference did not reach statistical significance. Regression analysis revealed that 
CRP, triglycerides, age, and plasma glucose were the strongest predictors of 
reduced circulating CD34+KDR+ cells (adjusted R-squared = 0.147, model p = 
0.01).
1.3.2 EPCs in patients with established cardiovascular disease
To assess the role of EPCs in coronary artery disease (CAD), Vasa et al [13] 
studied 45 subjects with angiographic evidence of coronary artery disease and 15 
healthy controls. They measured EPC number with cell culture (number of cells 
adherent to fibronectin after 4 days culture in EBM with dual positive staining 
for LDL and lectin), flow cytometry (circulating CD34+/KDR+) and migratory 
function was assessed with a modified Boyden chamber (for 24 hours, with 
VEGF as a chemo attractant). To determine the influence of atherosclerotic risk 
factors, a risk factor score including age, sex, hypertension, diabetes, smoking, 
positive family history of CAD, and LDL cholesterol levels was used.
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The number of risk factors was significantly correlated with a reduction of 
cultured EPC levels (R=-0.394, P=0.002) and CD34+/KDR+ cells (R=-0.537, 
PO.OOl). Analysis of the individual risk factors demonstrated that smokers had 
significantly reduced levels of cultured EPCs (P<0.001) and CD34+/KDR+ cells 
(P=0.003). EPCs isolated from patients with CAD also revealed an impaired 
migratory response, which was inversely correlated with the number of risk 
factors (R=-0.484, P=0.002). By multivariate analysis, hypertension was 
identified as a major independent predictor for impaired EPC migration 
(P=0.043). The authors concluded that the correlation with risk factors, and the 
reduced levels and functional impairment of EPCs observed may contribute to 
impaired vascularisation in patients with CAD.
Yue et al [14] performed a cross sectional observational study of 174 patients 
with established CAD. They found significantly lower circulating log 
CD34/KDR(+) EPCs in smokers compared with non-smokers (0.86 ± 0.03 vs 
0.96 ± 0.03 x 10_3/ml, p = 0.032). Smokers with elevated pulmonary artery 
systolic pressure (PASP) also had significantly lower circulating EPCs, higher 
pulmonary vascular resistance, and larger right ventricular dimensions with 
impaired function. Log CD34/KDR+ and log CD133/KDR+ EPC counts were 
significantly and negatively correlated with PASP (r = -0.30, p <0.001, and r = 
-0.34, p <0.001, respectively) and pulmonary vascular resistance (r = -0.29, p = 
0.002, and r = -0.18, p = 0.013, respectively). The reduced number of circulating 
EPCs and elevated PASP in smokers with CAD suggests that in smokers,
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depletion of circulating EPCs might be linked to the occurrence of pulmonary 
vascular dysfunction.
Schmidt-Lucke el al [15] measured circulating EPCs (defined as CD34+ KDR+ 
on flow cytometry) in 120 patients with acute coronary syndrome, stable 
coronary artery disease and control subjects. Patients were followed up for a 
median 10 month period and the primary outcome was cardiovascular events 
(cardiovascular death, unstable angina, myocardial infarction, PTCA, CABG, or 
ischaemic stroke).
They found that patients suffering from cardiovascular events had significantly 
lower numbers of EPCs (P<0.05). Reduced numbers of EPCs were associated 
with a significantly higher incidence of cardiovascular events by Kaplan-Meier 
analysis (P=0.0009). By multivariate analysis, reduced EPC levels were a 
significant, independent predictor of poor prognosis, even after adjustment for 
traditional cardiovascular risk factors and disease activity (hazard ratio, 3.9; 
P<0.05).
Werner et al [16] measured CD34+ KDR+ cells with flow cytometry in 519 
patients with coronary artery disease as confirmed on angiography, and patients 
were followed up for 12 months. After adjustment for age, sex, vascular risk 
factors, and other relevant variables, they found that increased levels of 
endothelial progenitor cells were associated with a reduced risk of death from
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cardiovascular causes (hazard ratio, 0.31; 95 percent confidence interval, 0.16 to 
0.63; P=0.001), a first major cardiovascular event (hazard ratio, 0.74; 95 percent 
confidence interval, 0.62 to 0.89; P= 0.002), revascularization (hazard ratio, 0.77; 
95 percent confidence interval, 0.62 to 0.95; P=0.02), and hospitalization (hazard 
ratio, 0.76; 95 percent confidence interval, 0.63 to 0.94; P=0.01). However, EPC 
levels were not predictive of myocardial infarction or of death from all causes. 
The authors concluded that the level of circulating EPCs predicts the occurrence 
of cardiovascular events and death from cardiovascular causes and may help to 
identify patients at increased cardiovascular risk.
Chen et al [17] cultured EPCs from 74 patients with Type 2 diabetes with and 
without critical leg ischaemia, and non-diabetic patients with and without lower 
extremity vascular disease. A modified Boyden chamber with VEGF as a chemo- 
attractant was used to assess cultured EPC migratory function in vitro. The 
migratory function was significantly impaired in diabetic patients without (48 
count/view/well) and with (51 count/view/well) critical leg ischaemia and non­
diabetic patients with critical leg ischaemia (49 count/view/well) compared with 
healthy subjects (63 count/view/well), p < 0.0001. As the migratory function of 
EPCs was impaired in patients with Type 2 diabetes, even in those without 
critical leg ischaemia, the authors postulate that Type 2 diabetes may alter EPC 
function and may account for the impaired neovascularisation and more 
aggressive clinical course in the development of critical limb ischaemia in 
patients with Type 2 diabetes compared with non-diabetic patients.
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1.3.3 Reversible defects in EPC number and function in patients with an
increased cardiovascular risk
The Austrian group mentioned above conducted a prospective randomised 
control trial of 40 patients with symptomatic peripheral arterial disease [11].
They measured EPC by flow cytometry (CD34+/KDR+/CD133+) and cell 
culture, and EPC migration was assessed using a modified Boyden Chamber. 
After 6 months of Supervised Exercise Training, they noted a significant increase 
in both measurements of EPC number, and migratory activity was also 
significantly increased.
Heida et al [18] studied EPC number and function in obese patients before and 
after weight loss in 49 obese (body mass index 42 +/- 7 kg/m2) and 49 age- 
matched lean volunteers. EPC number and function (migration through a 
modified Boyden chamber, adhesion to fibronectin and angiogenesis with 
HUVEC/Matrigel assay) were assessed at baseline, and in obese subjects who 
lost weight after 6 months (defined as current BMI <35 kg/m2 and/or >10% loss 
of body weight compared with baseline).
At baseline they found that obese subjects had lower EPC count, and that the 
cultivated EPCs displayed impaired adhesion, impaired migratory activity and an 
impaired ability to incorporate into network-like structures. The investigators 
went on to study the EPCs in vivo using a mouse hind limb ischaemia model. 
When injected into the mice, labelled EPCs from obese subjects were less
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frequently detected within the ischaemic hind limb musculature after 10 days (28 
+/- 25 vs. 88 +/- 85 chloromethylbenzamido-Dil-positive cells/mm2; p = 0.017;
11 mice per group). They also found that mice treated with EPCs from obese 
subjects revealed a reduced angiogenic response as assessed by the number of 
CD31-positive cells per square millimeter (p = 0.036 vs. lean).
After 6 months weight loss, 26 subjects had repeat sampling for EPC number and 
function. There was no change in medications over the period and mean weight 
loss was 26kg, and BMI dropped from 43 to 35 Kg/m2, (p <0.001 for weight and 
BMI differences from baseline). There was no significant difference in fasting 
glucose, total cholesterol or rates of hypertension, but serum triglycerides were 
lower (114 vs 149 mg/dl, p = 0.004) as was LDL cholesterol (115 vs 126 mg/dl, 
p = 0.024) when compared to pre-weight loss values.
Weight loss seemed to restore the number of acetylated low-density lipoprotein, 
lectin double-positive EPCs (p < 0.05 vs. initially obese, 10 per group). Weight 
loss also improved the adhesive properties of EPCs on flbronectin (p < 0.05 vs. 
initially obese), it normalised the migratory activity of EPCs (p < 0.001 vs. 
initially obese and p > 0.05 vs. lean; 8 per group), it and restored their angiogenic 
properties in the Matrigel assay (p < 0.01 and p > 0.05, respectively; n = 7).
In summary, when compared to lean controls, obese subjects have reduced EPC 
numbers, these cultivated EPCs are characterised by reduced adhesive and 
migratory capacity, and that these defects of EPCs are reversible after significant 
weight loss.
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1.3.4 Statins and EPC biology
HMG-CoA reductase inhibitors (Statins) inhibit the rate limiting step in the 
formation of cholesterol, resulting in a reduction in serum cholesterol levels and 
a reduction in cardiovascular risk. In addition they have anti-inflammatory and 
anti-thrombotic properties, and are also thought to reduce cardiovascular risk 
independent of their lipid lowering properties [19]. Given the links between 
EPCs and cardiovascular disease, and the beneficial effects of statins in 
cardiovascular disease, there have been a number of studies on the effects of 
EPCs and statins.
Dimmeler et al [9] found that atorvastatin increases the number of differentiated 
adherent EPCs (dual positive Lectin/DiLDL cells) when incubated with human 
mononuclear cells at day 3 of culture. To test the in vivo relevance of their 
findings, mice were fed with simvastatin (20 mg/kg daily) for 3 weeks, and EPC 
numbers were determined. Statin treatment led to a more than twofold increase in 
DiLDL/lectin-positive cells, thus extending the in vitro data.
Published in the same edition of the Journal of Clinical investigation, Llevadot et 
al [20] used a modified Boyden chamber with simvastatin, VEGF, or vehicle as a 
chemoattractant. Simvastatin profoundly enhanced EPC migration (control 
versus 1 jiM simvastatin, 5 ± 4 vs. 213 ± 46 cells per four high-powered [40x] 
fields; p <0.01). Migration with 10 pM simvastatin was equal to VEGF, and the 
maximum migration was seen with 1 jjM simvastatin. To investigate the effects 
of simvastatin on EPC mobilization, a chemotactic transwell assay was used.
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Chemotactic activity was increased by simvastatin, with maximum chemotactic 
activity observed in the group treated with 1 pM simvastatin (control versus 1 
pM simvastatin: 1,137 ± 148 vs. 4,681 ± 598 cells per 50 pi of lower chamber 
media; P < 0.01).
To evaluate EPC mobilization in vivo, a murine EPC culture assay was used as a 
functional index of circulating EPCs. After 4 days in culture, there were 
significantly more circulating EPCs in the peripheral blood of simvastatin-treated 
versus control mice (205 ± 5 vs. 147 ± 7 cells/mm2; P < 0.05) There was no 
statistically significant difference in the levels of serum cholesterol between 
treated and control mice.
To establish whether the in vitro and in vivo findings suggesting pro- 
vasculogenic effects of simvastatin on EPCs were associated with augmented 
neovascularisation, simvastatin therapy was studied in a murine model of corneal 
injury after bone marrow transplant. Simvastatin treatment resulted in augmented 
corneal neovascularisation and in more X-gal-positive cells than in the control 
group.
Sections from the simvastatin group documented more neovascularisation and 
more extensive incorporation of P-gal-positive cells compared with controls. 
Quantitative analysis of incorporated P-gal-positive cells revealed that 
simvastatin enhanced vasculogenesis in neovascular foci of corneas of 
simvastatin-treated versus control mice (25.7% ± 4.0% versus 7.3% ± 2.0% 
incorporation of P-gal-positive cells; P < 0.05). This study demonstrated that
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simvastatin enhances EPC migration and chemotaxis in vitro, and that it 
increases EPC mobilisation from the bone marrow in vivo.
A recent trial by Tousoulis et al [21] evaluated EPCs (flow cytometry, 
CD34+/KDR+) in rosuvastatin treatment in patients with heart failure (21 
patients assigned rosuvastatin lOmg/day, 18 assigned placebo). Rosuvastatin 
significantly increased circulating (CD34+/KDR+) EPCs, from 230 (170-380) to 
390 (230-520), p = 0.004. This increase in the number of EPCs did not correlate 
with the decrease in LDL (r=-0.12, p = 0.375). No differences were observed 
regarding the origin of heart failure, and subgroup analysis showed that the 
increase in EPC numbers was similar in subjects with ischaemic and non- 
ischaemic disease (46% and 36%, respectively, p = 0.63).
1.3.5 The effect on EPC number of other interventions known to reduce 
cardiovascular risk
1.3.5.1 EPCs and treatment of diabetes
Liao et al [22] quantified EPC number by flow cytometry (CD 45- / CD34+ / 
VEGFR2+) and endothelial function was assessed by flow-mediated brachial 
artery dilatation (FMD) in 46 newly diagnosed type 2 diabetic patients and 51 
healthy subjects. Metformin was then administered to all patients for 16 weeks.
The EPC number in the diabetic group was significantly lower than that in the 
control group (p < 0.001), and improved markedly after treatment (p < 0.001). 
The results of FMD were consistent with EPC variations among the three groups
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(p < 0.001). In multivariate regression analysis, the EPC number was an 
independent risk factor for FMD at baseline (p < 0.05). The absolute changes of 
EPC number showed significant correlation with the changes of FMD before and 
after treatment (r = 0.63, p < 0.001). The authors concluded that circulating EPC 
number was related to endothelial function and could be considered as a 
surrogate biological marker of endothelial function in Type 2 diabetes.
The same group [23] also evaluated treatment with gliclazide in type 2 diabetes. 
They quantified EPC number in 58 patients with newly diagnosed diabetes and 
control subjects. Baseline EPC count was lower in the diabetic group than in the 
control group at baseline (Cell count 1036±94 vs 1624±91, p<0.05), and 
improved significantly following 12 weeks of gliclazide treatment (Cell count 
after gliclazide 1411±106 vs 1036±94 at baseline, p<0.05).
1.3.5.2 EPCs and treatment of hypertension
Cacciatore ei al [24] measured EPC number by cell culture and migratory 
function with a modified Boyden chamber (VEGF as chemoattractant) in 
hypertensive patients before and after treatment with an ACE-Inhibitor (enalapril
20 mg/day (n=18) or zofenopril 30 mg/day (n=18)). Carotid intimal medial 
thickness (IMT) was determined by ultrasonography at baseline and after 1 and 5 
years of follow-up. There were no statistical differences between treatment 
groups during the follow up.
EPC number increased during the follow-up (69.6±12.0 vs. 80.6±8.4 for 
enalapril, 67.5±11.9 vs. 80.9±7.3 for zofenopril, p<0.001), but migrating capacity
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of EPCs did not change. There was an inverse correlation between circulating 
EPCs and IMT increase over time. Multiple linear regression model 
demonstrated that carotid IMT was significantly inversely correlated with EPC 
(p<0.001) but not with migratory cells after adjusting for confounders.
1.3.5.3 EPCs and treatment of subclinical hypothyroidism 
Subclinical hypothyroidism (SCH) has been associated with atherogenic lipid 
profile and endothelial dysfunction (assessed by flow-mediated dilatation), which 
improves with thyroid hormone replacement therapy [25]. Some studies have 
shown association of SCH and cardiovascular disease or mortality [26].
Shakoor et al [27] measured EPCs with cell culture and flow cytometry 
(CD34+/VEGFR-2+) and function (MMT assay) in 20 subjects with subclinical 
hypothyroidism (median TSH 6.5 mU/L) before and after 3 months thyroxine 
replacement (median TSH 2.26 mU/L), and 20 healthy controls (HC).
Flow cytometry EPC count was significantly reduced in SCH compared to HC 
(0.10 vs. 0.39, P < 0.001), and after treatment with thyroxine, EPC count 
increased to a similar level as HC (0.26 vs. 0.10, P < 0.001). EPC count as 
assessed by cell culture showed similar results (HC: 49 (46 -54) SCH at 
baseline: 47 (36 -54) p=0.06, SCH after treatment: 50 (32-79) p=0.08) but there 
was no difference in EPC function.
There was a significant positive correlation between EPCs with free T4 levels (r 
= 0.38; P = 0.02); high-density lipoprotein cholesterol levels (r = 0.51; P =
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0.001); and negative correlation with TSH concentrations (r = -0.64; P < 0.001). 
SCH appeared to be the single, most important factor determining lower EPC 
count when corrected for other cardiovascular risk factors studied, which 
excludes the possibility that the reduction in EPC count could have been 
secondary to prevailing risk factors.
1.3.6 Beneficial effects of infusion of EPCs in animal models of ischaemia
Since Asahara’s first demonstration of the role of the EPC in an animal model of 
ischaemia, there have been many subsequent studies confirming the same 
findings. A further study from the same group [28] transplanted ex vivo expanded 
human Dil-labelled EPCs to athymic nude mice with hind limb ischaemia. Blood 
flow recovery and capillary density in the ischaemic hind limb were markedly 
improved, and the rate of limb loss was significantly reduced. Time-course 
studies demonstrated that peak EPC incorporation was achieved within 3-7 days 
post administration of EPCs.
Review of sections retrieved from the ischaemic limbs animals identified labelled 
EPCs in up to 56 ± 4.7% (mean ± SEM, range 30-80%) of vessels in a x 10 field. 
Other than in ischaemic tissue and very rarely in the spleen, EPCs were detected 
neither in other organs nor the contra lateral non-ischaemic hind limb. This 
experiment confirmed the concept that ex vivo expanded human EPCs may have 
utility as a "supply-side" strategy for therapeutic neovascularisation.
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An experiment from the same laboratory in Boston [29] sought to clarify the 
extent to which EPCs contribute to adult neovascularisation. The investigators 
studied the quantitative contribution of EPCs to newly formed vascular structures 
in an in vivo Matrigel plug assay and corneal micropocket assay. They 
transplanted irradiated mice with bone marrow mononuclear cells from 
transgenic mice constitutively expressing beta-galactosidase (beta-gal). After 4 
weeks a subcutaneous matrigel plug containing fibroblast growth factor 2, or 
corneal pellet containing VEGF was injected, and mice were sacrificed 7 days 
later.
Bone marrow derived cells in the implants were identified by immunostaining 
for beta-gal, and 26.5% of all endothelial cells in the new blood vessels in the 
matrigel plug stained positive. In the comeal implant, 17.7% of the endothelial 
cells involved in neovascularisation were found to be bone marrow derived. Ki67 
staining of the comeal tissue documented that the majority of EPC-derived cells 
were actively proliferating in situ. These findings suggest that bone marrow 
derived EPCs make a significant contribution to angiogenic growth factor- 
induced neovascularisation.
Kawamoto et al [30] from the same group investigated transplanted human EPCs 
in an athymic rat model of myocardial ischaemia. Labelled human expanded 
EPCs were injected intravenously 3 hours after ligation of the left anterior 
descending artery. After 7 days intravenous lectin was administered and the 
animals were immediately sacrificed. Fluorescence microscopy revealed that
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transplanted EPCs accumulated in the ischaemic area and incorporated into foci 
of myocardial neovascularisation. To determine the impact on left ventricular 
function, 5 rats (EPC group) were injected intravenously with 106 EPCs 3 hours 
after ischaemia; 5 other rats (control group) received culture media.
Echocardiography showed that the EPC group had ventricular dimensions that 
were significantly smaller and fractional shortening that was significantly greater 
in the than in the control group by day 28. Regional wall motion was also better 
preserved in the EPC group. Histological examination disclosed that capillary 
density was significantly greater in the EPC group than in the control group. 
Moreover, the extent of left ventricular scarring was significantly less in rats 
receiving EPCs than in controls, hnrnunohistochemistry revealed capillaries that 
were positive for human-specific endothelial cells. The authors therefore proved 
that ex vivo expanded EPCs incorporate into foci of myocardial 
neovascularisation and have a favourable impact on the preservation of left 
ventricular function.
Aicher et al [31] from the same German group mentioned above (Schmidt- 
Lucke, Vasa, Dimmeler) performed a similar experiment with transplanted 
human EPCs in an athymic rat model of myocardial ischaemia. However they 
labelled the EPCs with a radioactive Indium tracer to monitor tissue distribution 
of the transplanted EPCs. 8 rats had an induced myocardial infarction, 8 had a 
sham operation and scintigraphic images were acquired 1, 24, 48, and 96 hours 
after EPC injection. At 24 to 96 hours after intravenous injection of EPCs,
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approximately 70% of the radioactivity was localized in the spleen and liver, 
with only approximately 1 % of the radioactivity identified in the heart of sham- 
operated animals.
After myocardial infarction, the heart-to-muscle radioactivity ratio increased 
significantly, from 1.02+/-0.19 in sham-operated animals to 2.03+/-0.37 after 
intravenous administration of EPCs. Injection of EPCs into the left ventricular 
cavity increased this ratio profoundly, from 2.69+/-1.54 in sham-operated 
animals to 4.70+/-1.55 (P<0.05) in rats with myocardial infarction.
On pathological examination, immunostaining of infarcted hearts confirmed that 
EPCs homed predominantly to the infarct border zone. They concluded that 
although only a small proportion of radiolabelled EPCs were detected in 
nonischaemic myocardium, myocardial infarction profoundly increases homing 
of transplanted EPCs in vivo.
1.3.7 Human Studies of EPC administration
The same Frankfurt group published the Transplantation of Progenitor Cells and 
Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI) 
trial in 2002 [32]. This pilot study aimed to evaluate the safety and feasibility of 
autologous EPC transplantation in humans with ischaemic heart disease.
The authors randomly allocated 20 patients with reperfused acute myocardial 
infarction (AMI) to receive intracoronary infusion of either bone marrow-derived
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(n=9) or circulating blood-derived progenitor cells (n=l 1) into the infarct artery 4 
days after AMI.
EPCs were isolated from the patients’ own blood and cultured on fibronectin 
coated plated prior to re-suspension, and bone marrow derived mononuclear cells 
(containing heterogeneous cell populations including hematopoietic progenitor 
cells) were isolated by density gradient centrifugation on the same day as 
infusion. Cells were administered in a 10ml direct infusion into the infarcted 
vessel during angiography.
Transplantation of progenitor cells was associated with a significant increase in 
global left ventricular ejection fraction from 51.6 to 60.1% (P=0.003), improved 
regional wall motion in the infarct zone, and profoundly reduced end-systolic left 
ventricular volumes at 4-month follow-up. In a non-randomized matched 
reference group, left ventricular ejection fraction only slightly increased from 51 
to 53.5%, and end-systolic volumes remained unchanged. There were no 
differences for any measured parameter between blood-derived or bone marrow- 
derived progenitor cells and no signs of an inflammatory response or malignant 
arrhythmias were observed.
Despite the fact that there was no randomised control group, and the study was 
non-blinded, the authors showed that intracoronary infusion of autologous 
progenitor cells appears to be feasible and safe and may beneficially affect the 
post-infarction remodelling processes.
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In 2003 a group in Japan [33] harvested CD34+ cells from peripheral blood and 
injected them into patients with critical limb ischaemia that were not suitable for 
surgical or percutaneous revascularisation. 2 patients were studied, both received 
granulocyte colony-stimulating factor (G-CSF) prior to the procedure, and cells 
were injected directly into the muscle of the ischaemic limb.
Transcutaneous oxygen pressure in the foot increased, clinical symptoms 
improved and newly visible collateral blood vessels were directly documented by 
angiography. Although this study was very small, and there was no control group 
to receive either G-CSF or placebo, the results add to the hitherto predominantly 
animal-derived evidence for a key role of the EPC in revascularisation.
In 2005 the first randomized placebo-controlled study of progenitor cells in 
coronary artery disease was published by Erbs at al [34], The group recruited 26 
patients with chronic total occlusion of a coronary artery and evidence of 
myocardial ischaemia or regional wall motion abnormality on cardiac imaging. 
GCSF was administered to increase the circulating number of EPCs, and after 4 
days mononuclear cells were isolated from peripheral blood by density 
centrifugation. Cells were cultured for 4 days in endothelial medium in gelatin 
coated flasks, and 90% of the cells bound lectin and took up Dil-acLDL. After 
recanalization of the occlusion, patients were randomly assigned to receive 
intracoronary infusion of day 4 EPCs or control serum. Coronary flow reserve in 
response to adenosine was measured in the target vessel at the beginning of the
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study and after 3 months. Left ventricular function and infarct size were assessed 
by MRI and metabolism by 18F deoxy-glucose positron emission tomography.
In patients administered day 4 EPCs there were statistically significant 
improvements in coronary flow reserve, and the number of hibernating segments 
in the target region had declined in the treatment group, whereas no significant 
changes were observed in the control group. MRI revealed a statistically 
significant reduction in infarct size by 16% and an increase in LV ejection 
fraction by 14% in the treatment group, because o f an augmented wall motion in 
the target region. There were similar rates of re-stenosis in both groups (25% vs 
27% in control).
This study proved that intracoronary transplantation of EPCs after recanalization 
results in an improvement of macro- and micro-vascular function and contributes 
to the recruitment of hibernating myocardium.
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1.4 Summary
In summary, EPCs are bone-marrow derived stem cells that are postulated to 
contribute to post-natal vasculogenesis and to repair of damaged endothelium by 
incorporation into the vessel wall, secretion of paracrine hormones and 
stimulation of angiogenesis. Since their original description in 1997, EPCs have 
been widely studied in cardiovascular disease, and a lower level of circulating 
EPCs and reduced EPC function in vitro are associated with an increased 
cardiovascular risk. Medications that reduce an individual’s cardiovascular risk 
have been shown to increase EPC number, and in animal models and human 
studies EPC infusions have been shown to increase blood flow to areas of 
ischaemia.
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2.1 EPCs in Pregnancy, and indirect evidence for the role of the EPC in low birth 
weight and future cardiovascular risk
Umbilical cord blood is a rich source of haemopoietic progenitor cells [35], and 
in 2001, Murohara et al [36] found that EPCs could be generated more efficiently 
from umbilical cord blood than from peripheral blood. They grew CD34+ cells 
from the mononuclear layer of human umbilical cord blood in an endothelial 
medium on fibronectin coated plates. After 7 days in culture endothelial 
phenotype was confirmed with uptake of Di-I-acLDL and formation of NO. 
When injected into an immunodeficient mouse ischaemia model, blood flow was 
augmented and the cells participated in capillary networks in ischaemic tissue. 
Subsequent studies have found that EPC numbers when cultured from cord blood 
are 15 times higher, and their population doubling time is 2.5 times faster than 
those cultured from adult peripheral blood [37]. Umbilical cord blood, therefore, 
is a very rich source of EPCs, and the expanded EPCs participate in 
neovascularisation in vivo.
Oestrogen levels are high during pregnancy, and oestrogen levels are thought to 
account for some of the differences in the incidence of cardiovascular disease 
between men and women [38]. Oestrogen alters serum lipid concentration and 
has a direct vasodilatory effect on blood vessels by affecting the bio-availability
Chapter 2. Pregnancy
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of endothelial derived nitric oxide [39]. There is also emerging evidence of the 
role that oestradiol has on EPC mobilisation, proliferation and apoptosis:
Asahara’s group [40] investigated the role of oestradiol in EPC mobilisation 
using a carotid injury model in oophorectamised mice receiving 176-ocstradiol or 
placebo. They found that oestradiol accelerates re-endothelialisation and 
attenuates medial thickening after carotid injury in part by augmenting 
mobilisation and proliferation of bone marrow-derived EPCs and their 
incorporation into the recovering endothelium at the site of injury.
The same laboratory further investigated oestrogen regulation of physiological 
postnatal vasculogenesis by modulating the bioactivity of EPCs through the 
oestrogen receptor [41]. They used peripheral blood and bone marrow derived 
EPCs and measured neovascularisation in cyclic hormonally regulated mouse 
uterine endometrium. Under the physiological concentrations of estrogen (1713- 
estradiol, E2), proliferation and migration were stimulated, whereas apoptosis 
was inhibited on day 7 cultured EPCs. These oestrogen-induced activities were 
blocked by a receptor antagonist. An in vitro assay for colony forming unit 
activity as well as flow cytometry using human EPCs at 5 different stages of the 
menstrual cycle revealed cycle-specific regulation of EPC kinetics. Their 
findings demonstrated that physiological postnatal vasculogenesis involves 
cyclical, oestrogen regulated bioactivity of BM-derived EPCs.
In order to further elucidate the role of oestrogen and EPCs during pregnancy, 
Sugawara et al [42] examined the level of serum oestradiol and circulating EPCs
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in 20 uncomplicated pregnancies at various degrees of gestation. Peripheral 
blood mononuclear cells were cultured on fibronectin coated plates in endothelial 
medium and at day 7 cells stained dual positive for Dil-acLDL and Lectin. More 
than 80% of the adherent cells expressed von Willebrand factor, KDR/Flk-1,
CD31, and ecNOS. The number of circulating EPCs increased gradually and 
paralleled the progression of gestational age. In addition, the number of EPCs 
correlated significantly with the level of serum oestradiol (r=0.722, p=0.0024). 
The fact that circulating EPCs increase with gestation in normal pregnancies, 
suggests that EPCs may play an important role in the regulation and maintenance 
of placental development and vascular integrity during pregnancy.
The authors of the study mentioned above also comment on the three adaptive 
mechanisms regulating maternal vascular development during pregnancy: 
vasodilatation, increased permeability, and neovascularisation. Up-regulated 
endothelial cells could contribute to these dynamic changes. In human 
pregnancy, flow-mediated vasodilatation of the radial artery has been shown to 
increase with gestational weeks [43]. Yoshida et al also found significantly less 
flow mediated dilatation in women with chronic hypertension and even less in 
women with pre-eclampsia (p<0.001 for normal vs. chronic hypertension vs. pre­
eclampsia). As mentioned above, Hill et al [8] found a significant correlation 
between the number of circulating EPCs and degree of flow mediated 
vasodilatation of the brachial artery.
Putting these findings together with Sugawara’s study, one can hypothesise that 
EPCs in the maternal circulation may contribute to the regulation and
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maintenance of placental development, and endothelium-mediated vascular 
integrity during pregnancy. Conversely, defects in EPC number or function may 
contribute to placental dysfunction and subsequent fetal growth restriction
Indirect evidence further supports a role for EPCs in placental and fetal 
development and subsequent determination of birth weight. Babies of smoking 
mothers are smaller at birth, and EPC numbers have been found to be lower in 
smokers. EPC number and function are reduced in pregnant women with pre­
eclampsia, an extreme manifestation of deficient placentation. Finally, a reduced 
degree of placentation has been found in patients with diabetes mellitus, another 
condition associated with EPC pathology:
2.1.1 Pre-eclampsia
Following their paper examining EPCs in normal pregnancy, Sugawara et al [44] 
cultured circulating EPCs from patients with pre-eclampsia (n=8) and 
normotensive pregnant women (n=7). They measured EPC number and EPC 
senescence by beta-galactosidase activity, and systemic inflammation was 
assessed with C-reactive protein measurement. They found that patients with pre­
eclampsia had lower median EPC number (10 vs. 34; P < 0.01), and a higher rate 
of cellular senescence (33.9 vs. 22.9; p<0.05) than in controls.
Patients with pre-eclampsia were divided into two subgroups on the basis of 
serum CRP, either positive (CRP >0.1 mg/dl; n=4) or negative (CRP <0.1 mg/dl; 
n=4). EPC count was markedly decreased in the CRP-positive group (5 vs 25; 
p<0.05), and there was a non-significant increase in cellular senescence when 
compared to the CRP-negative group. Although the numbers are small, these
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data suggest that the systemic inflammatory response observed in pre-eclampsia 
might be associated with the number and aging of circulating EPCs, which may 
lead to endothelial dysfunction and could be affected by systemic inflammation.
A subsequent similar Japanese study came to different conclusions. Matsubara et 
al [45] measured EPCs by flow cytometry (CD34+CD133+KDR+) and cell 
culture in 36 normal, 10 pre-eclamptic pregnancies and 20 non-pregnant control 
subjects. EPC proliferation was assessed with a commercially available ELISA 
kit, and angiogenesis was assessed by HUVEC/tubule formation. Of note median 
BMI was significantly higher in the pre-eclampsia group than in the normal 
pregnancy and control groups (28.4, 25.2 and 20.6 Kg/m2 respectively, p<0.001 
for pre-eclampsia vs. normal pregnancy). In contrast to Sugawara’s findings, the 
authors found that EPC number declined during pregnancy, and there was no 
difference in EPC number in pre-eclampsia vs. controls as measured by flow 
cytometry. They found a significant increase in both number of cultured EPCs 
and EPC proliferation in the pre-eclampsia group compared to the control group. 
They did not report quantification of tubule formation in the HUVEC assay. 
Although there are a number of methodological uncertainties in this study, it 
does raise the possibility that EPCs are up-regulated in pre-eclampsia.
Hwang et al. [46] measured fetal EPC number (flow cytometry and cell culture) 
and function (beta-galactosidase activity) in umbilical cord blood from normal 
pregnancies(n=30) and from pregnancies complicated by pre-eclampsia but 
without IUGR (n=17). They found that EPC number was significantly lower and
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cellular senescence was higher in the pre-eclampsia pregnancies when compared 
with healthy controls.
Kwon et al. [47] had similar findings when they measured umbilical cord blood 
EPCs and plasma VEGF in severe pre-eclampsia (n = 15) and normal pregnancy 
(n = 30). The severe pre-eclampsia group had significantly higher systolic blood 
pressure, lower birth weight, and higher rate of small for gestational age than the 
control group. Circulating EPCs in cord blood and umbilical cord plasma free 
VEGF were significantly decreased in severe pre-eclampsia compared to the 
control group (p = 0.009 and 0.04, respectively).
In conclusion abnormalities of EPC number and function seem to play a role in 
development of pre-eclampsia, but given some of the contrasting findings in 
different studies it is difficult to draw exact conclusions about the mechanisms 
involved until larger controlled studies are performed.
2.1.2 Smoking
Mothers who smoke during pregnancy are more likely to give birth to a smaller 
baby, and depending on the amount smoked the difference in birth weight 
compared to non-smokers ranges from 150-350g [48]. A study examining 
umbilical cord blood flow using doppler velocimetry showed a significant 
increase in the resistance index in the uterine arteries (P = 0.001) and umbilical 
artery (P = 0.001) in smoking compared to non-smoking pregnant women [49], 
EPC number and function is reduced in subjects who smoke [13, 50], and in 
subjects who are exposed to second hand cigarette smoke [51]. The combination
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of these findings is indirect evidence of the potential role of the EPC in birth 
weight.
2.1.3 Diabetes Mellitus
In a study of placental morphology of mothers with and without diabetes, Stoz et 
al [52] noted retarded maturation of the terminal villi and a decreased degree of 
vascularisation in the diabetic placentae when compared to the non-diabetic ones. 
Interestingly, they found that the degree of retardation ran in parallel with 
severity of diabetes, up until the most severe stage of diabetes, whose parameters 
were close to the normal placentae. The authors concluded that this was possibly 
due to a compensatory reaction of the fetal organ placenta to the reduction in 
utero placental blood flow in diabetes caused by diabetic angiopathy. It is well 
known that diabetes is associated with EPC pathology [53], and in patients with 
diabetes EPC proliferation correlates inversely with HbAlc [54]. These findings 
indirectly support the hypothesis that EPC pathology links defective placental 
vascularisation with future cardiovascular risk.
In summary, we hypothesise that EPC pathology results in defective maternal 
uterine spiral artery remodelling and reduced placental blood flow, which 
subsequently results in a low-birth weight baby, and that this EPC pathology is 
also responsible for the subsequent increased cardiovascular risk in the mother.
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2 . 2  E a r l y  p l a c e n t a l  v a s c u l a r  c h a n g e s
In order for healthy fetal development, an adequate blood supply through the 
placenta is required for the exchange o f oxygen, nutrients and waste products 
between mother and fetus. This blood supply develops rapidly and within a few 
weeks o f implantation, angiogenesis (the sprouting o f new vessels or elongation 
of existing ones) as well as vascularisation (the de novo formation of blood 
vessels from progenitor cells) can be found in the placental villi [55]:
The embryo implants about one week after conception, and within a further week 
the chorion undergoes rapid proliferation and forms numerous villi, which sprout 
in order to give a maximum area o f contact with maternal blood. Embryonic 
blood is carried to the villi by the branches o f the umbilical arteries, and after 
circulating through the capillaries o f the villi, is returned to the embryo by the 
umbilical veins.
These chorionic villi invade the uterine decidua during their 3 stages o f  
development: Primary chorionic villi are initially small non-vascular structures 
consisting only o f trophoblast, but at around 15-20 days post conception their 
cores become filled with mesenchymal cells thus generating secondary villi. At
21 days, progenitors o f haemangiogenic cells differentiate to form de novo blood 
vessels inside the mesochyme, and at this vascularisation stage the villi are 
termed tertiary. The receptors o f VEGF-R1 (Fit-1) and VEGFR-2 (Flk-1 or 
KDR) have been identified in the placenta [56], and knockout mouse 
experiments have shown that VEGFR-2 is vital for specification and early
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differentiation o f the haemangioblastic precursor cells into umbilical capillaries 
[57], The villous trophoblast o f this early stage o f development is considered to 
be paramount in regulating the development o f the placental vasculature [55].
Along with invasion o f the maternal decidua by the extravillous trophoblast, 
there must be profound remodelling o f the maternal vasculature in order to 
ensure normal development and function o f the placenta. Uterine spiral arteries 
are remodelled from narrow vessels into highly dilated, inelastic tubes, a process 
called decidualization, or ‘interstitial trophoblast-associated remodelling’ [58], 
This process o f spiral artery remodelling reduces maternal blood flow resistance 
and increases uteroplacental perfusion to meet the requirements o f the fetus. In 
addition, the loss o f contractility and maternal vasomotor control guarantees 
maternal blood supply to the placenta, irrespective o f maternal attempts to 
regulate the blood distribution within the body [59].
Remodelling takes place in three stages:
Very early in pregnancy, in the first phase o f remodelling, there are changes in 
the utero-placental arteries. These changes include vacuolation, endothelial 
basophilia, disorganisation or hypertrophy o f vascular smooth muscle and 
terminal luminal dilatation. This is thought to be a maternal response to 
pregnancy and occur independent o f trophoblast invasion [60], Prior to 
trophoblast invasion, in the second phase o f remodelling there are further 
changes in the vessel wall including dilatation, a reduction in smooth muscle 
cells, deposition o f fibrinoid material and accelerated nitric oxide production by 
the trophoblast [59]. The third phase involves infiltration o f the vessel wall by
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endovascular trophoblast cells. There is further reduction in the number of elastic 
fibres and smooth muscle cells and further dilatation, with an approximate 
threefold increase in original luminal diameter [55].
In summary, it is clear that an adequate blood supply is vital to supply nutrients 
and oxygen to the developing fetus. The development o f this blood supply is 
two-part, from both the trophoblast and decidua, and involves complex processes 
o f angiogenesis, vascularisation and vascular remodelling.
2.3 Pathology o f Intra Uterine Growth Restriction and its associations
Intrauterine growth restriction (IUGR) is defined as fetal growth less than the 
10th percentile for gestational age, although less than the 3rd percentile is 
probably a more reliable cut off for associated perinatal morbidity [61]. IUGR 
can be separated into symmetric and asymmetric types based on whether the 
head is spared or not. Symmetric IUGR is thought to be an early event, and is 
often either constitutional, or associated with a defined condition such as a 
chromosomal abnormality. The placenta in symmetrical IUGR is usually small, 
but free from pathological abnormalities. In contrast, asymmetrical IUGR is 
often associated with significant placental pathology, and most placental causes 
are due to maternal vascular compromise resulting in placental ischaemia [62]. 
This vascular compromise causing IUGR is often associated with hypertensive 
disorders in pregnancy, in particular the hyper-inflammatory condition o f pre­
eclampsia [63].
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Since the first reports o f the association between impaired maternal placental 
blood flow and hypertensive disorders o f pregnancy in 1953 [64], many groups 
have examined the reasons for, and implications o f inadequate placental vascular 
modification. There are still controversies as to the exact nature o f the 
trophoblast-decidua interaction described above, and it is still an area o f  
extensive research [58]. It is, however, clear that deficiencies in this complex 
process o f vascular remodelling has consequences for both mother and fetus.
Spontaneous miscarriage is often accompanied by a complete absence o f  
trophoblast invasion, while less severe deficiencies are associated with RJGR 
and early onset pre-eclampsia. This raises the possibility that all three syndromes 
are part o f a spectrum o f placental pathologies somehow linked to impaired 
conversion o f the spiral arteries [55].
In pre-eclampsia, the cytotrophoblasts fail to differentiate from an epithelial 
phenotype to an invasive endothelial phenotype. Instead, invasion o f the spiral 
arteries is shallow and they remain small calibre, resistant vessels [65], Common 
pathological findings o f pre-eclamptic placentas include medial disorganisation 
and hyperplasia in the myometrial arteries and acute atherosis in the decidual 
arteries [66].
The term ‘maternal placental syndrome’ has been applied to the presence o f  pre­
eclampsia, gestational hypertension, placental abruption, or placental infarction. 
This is because all o f  these conditions share some common pathological
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mechanisms, including diseased spiral arteries, placental ischaemia, and 
endothelial dysfunction [67].
Evidence o f the significance o f placental vascular compromise comes from a 
study published in The Lancet in 2005: A retrospective cohort study in Canada of
1 • 03 million women aimed to determine the future risk to the mother after 
maternal placental syndromes [68], 7% o f all pregnancies were complicated by 
maternal placental syndrome, and the mean age at delivery was 28 years for both 
those who were and were not affected. The average age at the time o f the first 
cardiovascular event was 38 years. Compared with those not affected, those 
affected were more frequently diagnosed with traditional risk factors for 
cardiovascular disease before delivery: hypertension, diabetes, obesity and 
dyslipidaemia; but there was no difference in smoking rates. They found a hazard 
ratio o f 2.0 (95 Cl 1-7-2-2) for future maternal premature cardiovascular disease 
following one o f the maternal placental syndromes. This risk was higher in the 
combined presence o f a maternal placental syndrome and poor fetal growth (HR 
3-1, 95 Cl 2-2-4-5) or a maternal placental syndrome and intrauterine fetal death 
(HR 4-4, 95 Cl 2-4-7-9). The gradient effect, with pre-eclampsia and intra­
uterine death having a higher hazard ratio than isolated gestational hypertension, 
suggests that women with more severe placental disease are at the highest risk of 
future cardiovascular disease.
The authors comment that their findings do not imply a causal relationship, and 
that the relationship is likely due to a woman’s abnormal metabolic milieu that 
predates her pregnancy and continues after delivery. They postulate that this 
chronic state o f dysmetabolism might create an inhospitable environment during
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the development o f the placental spiral arteries, which can adversely affect fetal 
health, while negatively affecting the large arteries o f a woman’s heart, brain, 
and extremities over a broader period o f time.
In summary, adequate vascular remodelling is vital to the development o f a 
healthy placenta and normal fetal growth. Defective placental development with 
reduced vascularisation and endothelial dysfunction are thought to play a role in 
the pathogenesis o f intra-uterine growth restriction and maternal placental 
syndromes. The presence o f disease in pregnancy is a strong predictor for future 
maternal cardiovascular disease, and the two may share common pathological 
mechanisms.
2.4 Birthweight and cardiovascular disease
Birthweight is influenced by a wide range o f environmental and genetic factors, 
including sex o f infant, maternal weight gain during pregnancy, maternal weight 
before pregnancy, maternal smoking, and socioeconomic conditions [69].
In his seminal paper in 1989, Barker published the results o f his analysis o f a 
birth cohort o f 5,654 men bom from 1911-1930 in Hertfordshire, UK [70]. 
Weight at birth and at 1 year o f age was correlated with future death from 
ischaemic heart disease. Hazard ratios for death from ischaemic heart disease fell 
with increasing birth weight. Men with the lowest weights at birth and at one 
year had the highest death rates from ischaemic heart disease (hazard ratios for 
death from ischaemic heart disease before 65 years o f age: 1.50 (95 Cl: 0.98-
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2.31) and 2.22 (95 Cl: 1.33-3.73) respectively. Similar epidemiological findings 
have subsequently been shown for women [71], and different ethnic populations 
[72],
This was the first conclusive evidence confirming Barker’s theory that coronary 
heart disease may be linked to impaired fetal growth [73]. In this paper, 
published 3 years prior to the study mentioned above, he first examined the 
differences in mortality in different socio-economic areas in the UK in the 
1960’s. It had been noted that northern industrial towns and poor rural areas had 
much higher death rates from coronary heart disease than the more affluent 
southern and eastern areas o f the country. These differences were in parallel to 
previous geographical differences in perinatal mortality rates. This association 
between infant and adult mortality did not seem to be purely due to dietary 
factors or poor social conditions, because the geographical distribution o f both 
dietary fat consumption and death from lung cancer were different to past infant 
mortality, and maternal smoking was very rare in the 1920s. This led Barker to 
look for adverse environmental effects both in utero and during infancy that 
increased susceptibility to cardiovascular disease. In the early 20th century the 
majority o f neonatal deaths occurred within a week o f birth, and were commonly 
associated with low birth weight. Hence the search for adverse intra-uterine 
factors, rather than post-natal influences in early infancy, and the evolution o f the 
fetal origins hypothesis: That fetal under-nutrition in middle to late gestation, 
which leads to disproportionate fetal growth, programmes later coronary heart 
disease.
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In 1995, Barker published a further article: Fetal origins o f coronary heart 
disease [74], in which he explores some o f  the mechanisms; Trends in coronary 
heart disease with birth weight are paralleled by similar trends in two o f its major 
risk factors, hypertension and non-insulin dependent (type 2) diabetes. The latter 
may be explained by the fact that thin neonates lack both fat and skeletal muscle, 
and one o f the responses to this is to develop insulin resistance. Numerous 
studies have shown that low birth weight is associated with raised blood pressure 
in childhood and adult life, and possible mechanisms include persisting changes 
in vascular structure, including loss o f elasticity in vessel walls, and the effects of 
elevated glucocorticoids. Disordered cholesterol metabolism and blood 
coagulation in adults have been linked to disproportionate size at birth, and this 
may be due to under-nutrition in late gestation, with ensuing elevated LDL 
cholesterol and fibrinogen levels. Failure o f infant growth may be due to growth 
hormone resistance, which is associated with high circulating levels o f the 
hormone, which may cause cardiac enlargement and atheroma in later life.
Finally there may be placental factors, as a disproportionately-sized placenta has 
been associated with future hypertension, impaired glucose tolerance, disordered 
blood coagulation, and death from coronary heart disease.
It should be noted that others have put forward alternative hypotheses to the fetal 
under-nutrition theory to explain the birth weight-future cardiovascular disease 
correlation. Hattersley and Tooke [75] propose that low birth weight, insulin 
resistance, and ultimately glucose intolerance, diabetes, and hypertension could 
all be phenotypes o f the same insulin-resistant genotype. Polygenic influences 
resulting in insulin resistance could explain abnormal vascular development
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during fetal life and early childhood, and also the increased risk o f hypertension 
and vascular disease in later life. They conclude that the predisposition to type 2 
diabetes and vascular disease is likely to be the result o f both genetic and fetal 
environmental factors.
Commenting on the origins o f his theory, Barker uses the concept o f  
developmental plasticity: a critical period when a system is plastic and sensitive 
to the environment, followed by loss o f plasticity and a fixed functional capacity 
[76]. For most organs and systems the critical period occurs in utero. These 
early-life metabolic adaptations help the survival o f the organism by selecting a 
growth trajectory appropriate to the environmental cues, in the case o f an adverse 
intra-uterine environment a ‘thrifty phenotype’. Those with a thrifty phenotype 
who later develop in an affluent environment may be more prone to metabolic 
disorders, such as obesity and type 2 diabetes, whereas those who have received 
a positive maternal forecast will be adapted to good conditions and therefore 
better able to cope with rich diets. This ‘programming’ o f risk o f future 
cardiovascular disease seen in fetal under-nutrition is particularly increased if  
there is over-nutrition and accelerated growth in the post-natal period.
2.5 Birthweight and future maternal cardiovascular risk
As discussed above, the inverse relationship between an individual’s birth weight 
and his or her cardiovascular risk in later life is well established, but there is 
increasing evidence that the mothers o f low birth weight babies also have an 
increased cardiovascular risk in later life.
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There is a strong correlation between an infant’s birth weight and its mother’s 
and, to a lesser extent, its father’s own birth weight. It was this inter-generational 
effect that first suggested that birth weight o f  offspring could possibly be 
associated with the risk o f  CVD mortality among parents [77]. Parents o f heavier 
babies would be expected to have lower mortality from cardiovascular disease 
than parents o f lighter babies. In order to explore whether intergenerational 
influences on birth weight are mirrored by mortality risk, Davey Smith et a l 
performed a prospective observational study on married couples in the West of 
Scotland [78]. The authors contacted married subjects who had been recruited 
into the Refnew and Paisley cohort study in the 1970s. If one or both o f the 
couple had died then information on offspring was obtained via the death 
certificate.Offspring birth weight was obtained from a centralised database (1134 
birth weights o f the offspring for 794 couples). Parents’ mortality was taken from 
another central register, and deaths were coded as cardiovascular or other.
They found that women who had heavier babies were taller, had higher body 
mass index and better lung function, and were less likely to be smokers than 
mothers o f lighter babies. Fathers o f heavier babies were taller and less likely to 
be smokers than fathers o f  lighter babies. All cause and cardiovascular mortality 
were inversely related to offspring's birth weight for both mothers (RR for a 1 kg 
lower birth weight 2.00 (95 Cl: 1.18, 3.33)) and fathers (1.52 (1.03 to 2.17)) for 
cardiovascular mortality. Adjustment for blood pressure, cholesterol, height,
BMI, social class and smoking had little effect on these risk estimates, although 
levels o f statistical significance were reduced.
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The authors comment that the strength o f the association was greater than would 
have been expected by the degree o f concordance o f birth weights across 
generations, but an extensive range o f potential confounding factors could not 
account for the association. They concluded that mortality is therefore influenced 
by an unknown factor related to birth weight that is transmissible across 
generations.
This was a relatively small study, but several subsequent studies confirm that 
offspring birth weight is associated with future parental mortality. Davey Smith 
et a l recently performed a meta-analysis o f the six published studies o f the 
association [79]. This meta-analysis encompassed data on 1.73 million people 
followed up for 10 to 34 years after the birth o f the offspring whose birth weight 
was used in the analysis. The authors found that among mothers, the pooled, 
adjusted hazard ratio o f cardiovascular disease mortality for a 1 -standard 
deviation (approximately 500g) increase in birth weight was 0.75 (95 Cl: 0.67, 
0.84) and, among fathers, the equivalent association was 0.93 (95 Cl: 0.91, 0.95), 
with statistical evidence o f a difference between these two effects (p < 0.001). It 
should be noted that only 2 out o f the 6 studies used birth weight that had been 
adjusted for pre-term delivery and gestational age. However these two studies did 
make up the vast majority o f the subjects studied (1.68 million), and therefore the 
association is likely to be related to genuine small for gestational age infants, and 
not just infants who happened to be bom prematurely.
As mentioned above, the association may reflect matemal/fetal nutritional factors 
and intrauterine programming, as women who themselves had poor fetal growth
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and low birth weight tend to have offspring who are small for their gestational 
age. This effect may be mediated via maternal pelvic restriction, poor placental 
growth, and hence a programming effect o f intrauterine nutrition across 
generations. One can also not rule out the potential effect o f shared 
environmental exposures such as cigarette smoking that would explain disease in 
both generations. Only two of the studies included in the meta-analysis made 
adjustments for parental smoking. However, in the original Refnew and Paisley 
study, adjustment for smoking had little effect on the risk estimates, although 
levels o f statistical significance were reduced (Relative maternal mortality for 1 
quintile increase in birth weight, unadjusted: 0.82 (95 Cl: 0.72, 0.94) p<0.01, 
after adjustment for all risks: 0.84 (0.73 to 0.97) p<0.05). In addition, if  smoking 
and socio-economic factors were the only reason for the association, then one 
would expect similar risks for the mother and the father, as they would both be 
exposed to the same environment. The slight, albeit statistically significant 
association seen in paternal mortality may well reflect socio-economic or 
environmental factors not captured by the studies. The fact that mothers have a 
higher risk than fathers implies that there are inherent maternal factors affecting 
intra-uterine growth over and above environmental ones.
In summary, the authors found that a reduction in birth weight o f 1 standard 
deviation (approx 500g) was associated with a 25% increased risk of future 
maternal cardiovascular mortality. The reasons for this relationship are not yet 
understood but maternal factors which affect intrauterine growth seem to have 
important influences on long-term mortality risk.
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2 . 6  T h e  p o t e n t i a l  r o l e  o f  t h e  E P C  i n  g r o w t h  r e s t r i c t i o n  i n  u t e r o  a n d  f u t u r e
cardiovascular disease in mother and infant
Considering the mechanisms o f angiogenesis and neovascularisation involved in 
placental development, and the future risk o f cardiovascular disease in the 
mother associated with their dysfunction, immediately raises the possibility that 
abnormalities o f EPC number or function may play a role. In addition, EPC 
pathology could explain Barker’s hypothesis, that sub-optimal intra-uterine 
growth is associated with future adult cardiovascular disease [76].
In a recent review in Placenta, Sipos et a l discuss the potential role o f the EPC in 
complications o f placental vasculature and long term cardiovascular risk in the 
infant [80]. They hypothesise that anomalies in either EPC number or function 
may impair formation o f normal placental vessels and influence the embryonic 
endothelium. On the maternal side, functional irregularities could affect uterine 
vessels, restricting or attenuating blood flow, thus perpetuating placental disease. 
Potential mechanisms put forward include hypoxia and oxidative stress, which 
are both proposed utero-placental features o f  pre-eclampsia and IUGR. In 
pathological conditions such as tissue hypoxia, EPC numbers and function may 
be impaired. In the setting o f excessive reactive oxygen species (ROS), reduced 
bioavailability o f nitric oxide could also influence EPC mobilisation and 
recruitment [80].
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We further hypothesise that in addition to playing a role in future cardiovascular 
disease in the infant, EPCs may also be involved in future cardiovascular disease 
in the mother.
5 7
C h a p t e r  3 .  A d i p o n e c t i n
3.1 Adiponectin as a biomarker for cardiovascular disease
The epidemic o f obesity and type 2 diabetes in recent years has focused much 
research attention on adipose tissue. One o f the more important results o f such 
research has been the finding that adipocytes do not merely function as inert 
repositories for energy stores, as previously thought, but can be considered as 
endocrine organs in their own right, synthesizing and releasing a number o f  
hormones, collectively known as adipokines, that have a diversity o f biological 
functions including the regulation o f energy homeostasis. Adiponectin is the 
most abundant adipokine secreted by adipose cells tissue that may couple 
regulation o f insulin sensitivity with energy metabolism. Some studies have 
suggested that adiponectin may provide the link between obesity, type 2 diabetes, 
insulin resistance and cardiovascular disease. This section will briefly review 
adiponectin, and the role that it may play in particular in diabetes-related and 
non-diabetes-related cardiovascular disease.
3.1.1 Background
Adiponectin, leptin, plasminogen activator inhibitor-1, resistin and tumour 
necrosis factor alpha are examples o f hormones released by adipose tissue. 
Adiponectin, the most abundant adipokine circulates in the blood in relatively 
large concentrations when compared to other hormones. A  30-kDa protein that 
consists o f an N-terminal collagenous domain and a C-terminal globular domain,
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adiponectin was first isolated in the mid 1990s. Under normal conditions, the 
adiponectin gene (AMP1) located on chromosome 3q27 is expressed exclusively 
in adipose tissue. Adiponectin circulates in the blood in higher-order multimeric 
structural forms including trimeric (low molecular weight, LMW), hexameric 
(middle molecular weight, MMW), and high molecular weight (HMW) 
complexes [81]; the majority o f studies that have linked adiponectin with 
metabolic diseases have used assays for total adiponectin [82]. In healthy 
populations, adiponectin levels vary with race and gender; serum adiponectin is 
lower in Indo-Asians when compared with Caucasians (median 3.3 vs. 4.9 
mcg/ml), and women have about 40% higher circulating levels o f adiponectin 
than men [83].
3.1.2 Adiponectin in type 2 diabetes
Many o f the initial adiponectin studies were performed in patients with obesity 
and Type 2 Diabetes (T2DM). Despite being a hormone secreted mainly by 
adipose tissue, adiponectin levels are paradoxically inversely correlated with 
body weight or body mass index, suggesting that a negative feedback loop exists 
between adiponectin and adipose tissue. Plasma adiponectin levels are reduced in 
obese individuals [84], particularly in those with visceral obesity, and levels o f  
adiponectin correlate inversely with the degree o f insulin resistance present in 
such individuals. Evidence also suggests that substantial weight loss can increase 
adiponectin levels [85].
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Reduced plasma adiponectin levels have also been found in patients with T2DM, 
and non-diabetic individuals with lower adiponectin levels at baseline have a 
higher future risk o f developing T2DM [86]. The converse is also true, with the 
Atherosclerosis Risk in Communities Study [87] reporting that higher 
adiponectin levels are associated with a lower risk o f later development o f  
T2DM. Low plasma adiponectin is also a predictor o f the metabolic syndrome 
independent o f body mass index [88].
Quite apart from the association between type 2 diabetes and adiponectin levels 
in many o f the studies quoted, a potential causative role for adiponectin in the 
pathophysiology o f T2DM has been suggested by a number o f studies. 
Administration o f adiponectin to insulin-resistant mice has an insulin sensitizing 
effect. Intra-peritoneal injection o f adiponectin leads to a fall in blood glucose in 
wild-type and ob/ob diabetic mice compared to non-injected control mice, and 
adiponectin enhanced insulin-induced suppression o f glucose production from 
isolated primary rat hepatocytes [89]. Over-expression o f adiponectin in ob/ob 
mice (an animal model o f obesity associated T2DM) protected against 
development o f diabetes and improved insulin sensitivity [90]. Also suggesting a 
causative role for adiponectin in type 2 diabetes is the fact that single nucleotide 
polymorphisms (SNPs) in the adiponectin gene are associated with T2DM in 
humans [91].
The presence o f abnormal adiponectin levels in the high cardiovascular risk state 
o f T2DM, and the association o f hypoadiponectinaemia with the components of 
the metabolic syndrome, such as insulin resistance, elevated triglycerides, and
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low HDL cholesterol [92], led to suggestions that low adiponectin levels in 
T2DM may provide the link between T2DM and cardiovascular disease. A  
number o f in vitro and animal studies, detailed below, appeared to support this 
contention by demonstrating a number o f beneficial effects o f adiponectin at a 
cellular level which could potentially reduce risk o f atheroma formation and 
cardiovascular disease.
3.1.3 Anti-inflammatory. Vasodilator and Anti-oxidant Effects
At a cellular level, adiponectin has been shown to have a number o f effects that 
could potentially reduce the risk o f developing atherosclerosis and cardiovascular 
disease. Adiponectin directly stimulates the production o f vasoprotective nitric 
oxide (NO) by endothelial cells, and enhances endothelial NO synthase (eNOS) 
activity. Adiponectin also improves the endothelium reduction-oxidation state by 
suppressing NADPH oxidase-derived superoxide generation [93], another action 
with potential benefits on endothelial function. Evidence also suggests that 
HMW adiponectin suppresses endothelial cell apoptosis [94] and promotes 
vascular healing and angiogenesis. Furthermore, adiponectin prevents 
macrophage transformation into foam cells, a crucial step in atherogenesis [95].
In animal studies, adiponectin-knockout mice have shown increased neo-intimal 
proliferation in response to vascular injury and administration o f adiponectin 
prevents atherosclerosis in apolipoprotein-E-deficient mice in vivo  [96]. Arita et 
a l [97] also showed that adiponectin suppresses proliferation o f human aortic 
smooth muscle cells, suggesting a possible influence on vascular remodelling.
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Taken together, the above in  vitro  and in  vivo  animal studies suggest that by 
acting as an anti-inflammatory, antioxidant and vasodilator agent among other 
effects, adiponectin can potentially prevent endothelial dysfunction and the 
progression o f atherosclerosis.
3.1.4 Beneficial effects in cardiovascular disease
A number o f epidemiological studies appeared to support this hypothesis, by 
demonstrating that plasma adiponectin levels are significantly lower in patients 
with coronary artery disease.
In one such study male patients with adiponectin levels o f less than 4 mcg/ml 
were found to have a 2-fold increase in coronary artery disease prevalence 
independent o f other known risk factors [98]. The fact that the relationship 
between adiponectin levels and cardiovascular disease persists after adjustment 
for possible mediators o f this effect such as diabetes, HDL and Body Mass Index 
suggested a direct effect o f  adiponectin in the vascular system.
A case control study from 2004 found that healthy subjects with adiponectin 
levels in the upper 20% range have a 2-fold reduced risk for myocardial 
infarction [99]. Also higher plasma adiponectin levels are independently 
associated with a lower risk o f acute coronary syndrome [100].
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In a population-based 10-year follow-up study in elderly men, Frystyk et a l [101] 
found that a 1 standard deviation increase in adiponectin levels was associated 
with a 23% reduction in risk o f coronary heart disease.
In the SAPHIR [102] study there was a negative association between common 
carotid artery intimal media thickness and adiponectin levels, again suggesting 
that hypoadiponectinaemia is a risk factor for the development o f  early 
atherosclerosis.
A  5-year follow-up study o f men with type 1 diabetes found adiponectin levels 
were inversely associated with BMI and directly associated with age, duration o f  
diabetes, and alcohol. Adiponectin was associated with a decreased risk for 
cardiac events, independent o f BMI, diabetes duration, age, smoking and lipid 
levels. The multivariate relative risk for CHD for a doubling o f  adiponectin was 
0.71 (95% Cl 0.53-0.95) [103].
Despite the apparent initial consensus on the relationship between adiponectin, 
diabetes and CV disease prompted by the studies detailed above, studies in type 1 
diabetes and some further cardiovascular studies have suggested that the 
relationship between adiponectin and cardiovascular disease/diabetes may not be 
as straightforward as initially suggested.
3.1.5 Type 1 diabetes
Although not a condition associated with obesity and insulin resistance, the 
strong associations found between low adiponectin levels and T2DM, the
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potential role for adiponeetin in the pathophysiology CV disease in type 2 
diabetes, and the high cardiovascular risk in type 1 diabetes inevitably led to 
studies o f adiponeetin in patients with type 1 diabetes (T1DM). Studies to date 
have indeed found abnormal adiponeetin levels in patients with T1DM, but, in 
contrast to the findings in subjects with T2DM and in subjects with obesity, 
paradoxical elevated adiponeetin levels have been found in T1DM subjects. In 
pre-pubertal children with uncomplicated T1DM, adiponeetin levels were found 
to be higher than in healthy controls, and a significant positive correlation was 
found between adiponeetin levels and HbAlc [104]. The Finnish Diabetic 
Nephropathy Study [105] found that increased serum adiponeetin levels predict 
the progression from macroalbuminuria to end-stage renal disease in type 1 
diabetic patients.
3.1.6 Association of adiponeetin with increased cardiovascular risk
In a sub-study o f the Hoorn Study [106], a population-based cohort study of 
diabetes and diabetes complications, the authors measured adiponeetin levels 
from 2484 patients aged 50-75yrs from the cohort and studied the association 
with cardiovascular disease and mortality data from 15 years o f follow up. At 
baseline, high adiponeetin levels were strongly associated with a more 
favourable CVD risk profile, with lower weight, smaller waist, higher HDL 
cholesterol and lower triglycerides, lower insulin and glucose levels, and lower 
ALT.
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On follow up, higher adiponeetin reduced the risk o f nonfatal CVD in women, 
but there was no statistically significant reduction in men, and there was no 
difference in men or women in the risk o f all-cause or CVD mortality. A  
subgroup analysis found that high adiponeetin levels were associated with 
increased  mortality risk in both sexes with prevalent CVD at baseline, and with 
reduced risk in people without prevalent CVD at baseline. After adjustment for 
conventional cardiovascular risk factors, the hazard ratios for CVD mortality 
were 1.60 (1.14 -2.23) for patients with and 1.38 (1.06 -1.80) for patients 
without prevalent CVD. (Hazard ratios with 95% confidence interval per SD 
change in log-adiponectin)
The underlying mechanisms for these contradictory results in the Hoorn study 
and in type 1 diabetes are still unclear. It has been speculated that low 
adiponeetin predicts cardiovascular events in low-risk populations for CVD, 
whereas in high-risk populations, a counter-regulatory increase o f adiponeetin 
occurs that represents an attempted defence mechanism against the 
cardiovascular alterations and the pro-inflammatory state associated with CVD, 
hence the paradoxical finding o f an elevated cardiovascular risk associated with 
high adiponeetin levels [107, 108]. Alternatively, resistance to adiponeetin due to 
down-regulation o f adiponeetin receptors may play a role. It is o f course 
possible, as the authors o f the Hoorn study warn, that adiponeetin also exerts 
harmful effects that contribute to the increased mortality risk associated with 
high adiponeetin. It is possible that initially beneficial effects o f adiponeetin on 
CVD might become deleterious in advanced CVD states, in particular when the 
compensatory increase o f  adiponeetin is overwhelming [106].
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3 . 1 . 7  S u m m a r y
In summary, adiponectin is a key adipokine with multiple actions in the human 
body. At a cellular level it has anti-inflammatory, anti-apoptotic, anti-atherogenic 
and vasodilator effects. High plasma adiponectin level is associated with a 
favourable lipid and glucose metabolism, and with a reduced risk o f CVD events 
in women. However, higher adiponectin levels have been associated with adverse 
outcomes, in particular in people with type 1 diabetes, advanced kidney disease 
or a history o f CVD. This may be due to a compensatory up-regulation of 
adiponectin in advanced disease stages, but a more precise explanation remains 
elusive.
It seems, therefore, that despite initial promise adiponectin will not be a useful 
biomarker o f disease or cardiovascular risk in all patient groups. Further research 
will be needed to elucidate the complex underlying molecular mechanisms 
involved before adiponectin can be used as a therapeutic target in cardiovascular 
disease. In the meantime, we can modify adiponectin levels and reduce 
cardiovascular risk in clinical practice by modifying the conventional and non- 
conventional risk factors for cardiovascular disease which have been associated 
with altered adiponectin levels, such as low HDL, obesity, insulin resistance, and 
poor glycaemic control.
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3 . 2  A d i p o n e c t i n .  b i r t h w e i g h t  a n d  c a r d i o v a s c u l a r  r i s k
As discussed above, adiponectin is the most abundant hormone released by 
adipocytes, and is thought to couple regulation o f  insulin sensitivity with energy 
metabolism[109]. It has anti-inflammatory, anti-apoptotic and anti-atherogenic 
properties [93-95], Some studies have suggested that adiponectin may provide 
the link between obesity, type 2 diabetes, insulin resistance and cardiovascular 
disease [82, 88, 89]. High levels are associated with favourable lipid and glucose 
metabolism, and a reduced risk o f cardiovascular events in women [106]. Altered 
maternal adiponectin levels have been found in women with gestational diabetes 
[110, 111] and pre-eclampsia [112].
The discrepancies in adiponectin levels in established cardiovascular disease or 
diabetes described above would not be expected to interfere with measurement in 
our cohort. In the Hoorn study [106], adiponectin correlated with non-fatal 
cardiovascular disease in women, and the increase in mortality associated with 
high adiponectin levels was only seen in the subgroup that had pre-existing 
cardiovascular disease. Our cohort was made up o f  women with a mean age of 
32 years and we excluded subjects with diabetes, significant medical illness or 
pre-existing cardiovascular disease. Hence adiponectin levels in our cohort could 
provide important information about future risk o f cardiovascular disease.
Low serum adiponectin has been found in adults and children bom small for 
gestational age, and cord blood adiponectin is independently associated with 
birth weight, with decreased levels characterising growth-restricted fetuses[l 13].
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It was this twin study by Mazaki-Tovi et al [113] that gave weight to the 
argument that the lower cord blood adiponectin levels were due to abnormal 
placentation and not attributable to genetic disparity. The authors postulate that 
the observed reduced adiponectin levels in SGA neonates could be due to 
decreased fetal adipose tissue depots and increased fetal exposure to hypoxia, 
both o f  which are features o f growth restriction.
It therefore seems that adiponectin has an important role in the regulation o f  
major metabolic pathways and fetal growth and it may form part o f the link 
between low birth weight and future metabolic complications in later life [113]. 
We planned to measure maternal and umbilical cord adiponectin levels in small 
for gestational age and appropriate gestational age control pregnancies.
6 8
C h a p t e r  4 .  M e t h o d s
Aims:
We aimed to investigate the link between EPCs, delivery o f a low birth weight 
baby, and risk o f future cardiovascular disease in the mother by measuring 
conventional cardiovascular risk markers and EPC number and function in 
mothers o f Small for Gestational Age (SGA) and Appropriate for Gestational 
Age (AGA) infants. We also aimed to measure maternal and cord blood 
adiponectin to further investigate the role o f adiponectin in birth weight and 
cardiovascular disease.
4.1 Inclusion and Exclusion Criteria. Patient Recruitment
Ethical approval for our study was obtained from the Research Ethics Committee 
in the Rotunda Hospital, Dublin (Chairman: Professor T. Clarke). The Rotunda 
Hospital is a large University Maternity Hospital with approximately 8,700 
deliveries per year. All patients and controls were recruited in the antenatal clinic 
and fetal assessment unit.
We attempted to exclude patients confounding factors that could influence EPC 
number or function; therefore subjects with fetal and maternal conditions were 
excluded, such as:
- Multiple gestation (more than one fetus in current pregnancy), fetal 
structural or genetic anomaly
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Pre-existing or gestational diabetes mellitus 
Pre-existing cardiovascular disease or hypertension
- Renal, hepatic or autoimmune disease 
Malignancy, anaemia, haemolysis or severe infection 
Current cigarette smoking, drug or alcohol use.
Patients and controls studied satisfied the following criteria:
- Twenty-four to thirty-two weeks gestational age at enrolment.
Gestational age confirmed by date o f last menstrual period, and/or first 
trimester ultrasound if  dates unknown, or menstrual cycle irregular.
- Able to comprehend the information sheet and consent form.
- Attending antenatal services in the Rotunda Hospital.
- Willingness to participate in study, and attend for fasting blood tests six 
weeks post-partum.
Recruitment of patients and controls was as follows:
Prior to each antenatal clinic, the charts o f all patients scheduled to attend were 
reviewed by the author, in order to find patients fulfilling the inclusion and 
exclusion criteria for the study. Appropriate patients were then approached at the 
time o f their clinic visit. The study was explained in detail and the patient 
information leaflet (information sheet, appendix 1) was given. After they had at 
least 24 hours to think about participation, if  the patients wished to volunteer for 
the study then written informed consent was obtained (consent form, appendix
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Mothers o f potential small for gestational age (SGA) babies were identified by 
ultrasound scanning and estimation o f fetal weight by bi-parietal diameter, head 
circumference, abdominal circumference and fetal length, using Hadlock’s 
method [114]. Controls matched for age, BMI and ethnicity were recruited in the 
same manner. Subjects were classified into 2 groups based on their EFW: AGA  
group (EFW >10* centile), and SGA group (EFW<10th centile).
Medical history and family history were obtained, blood pressure was checked, 
patients were weighed and height was measured. The details o f booking weight, 
blood pressure, urinalysis and laboratory investigations were recorded from the 
medical notes.
Patients were screened for diabetes as follows:
In our Hospital, routine oral glucose tolerance testing (OGTT) is only performed 
in patients who are obese, over 40 years o f age, from an ethnic group with a high 
prevalence o f diabetes, have a history o f polycystic ovarian syndrome (PCOS), 
have had previous macrosomia, have a first degree relative with type 2 diabetes 
or in those with glycosuria. All patients were screened for glycosuria at every 
visit. If patients in the study had not had an OGTT performed, or if  it was not 
scheduled to be performed, then they were screened with a blood test for glucose 
and HbAlc. The time o f the last meal was noted and if  the result was abnormal 
then a formal OGTT was performed, and patients were excluded from the study 
if  diabetes was confirmed. Diagnosis o f diabetes was based on the current 
consensus guidelines o f the American Diabetes Association (ADA) and 
European Association for the Study o f Diabetes (EASD)[115].
7 1
Gestational hypertension was defined as BP > 140/90mmHg, and pre-eclampsia 
was defined as hypertension and proteinuria (>300 mg o f protein in a 24-hour 
urine sample).
At the time o f delivery, 10ml o f umbilical cord blood was collected in EDTA 
coated bottles, stored at 4 degrees centigrade and transported to the laboratory. 
Mode o f delivery was recorded, and placental examination was performed by the 
local pathology department.
At delivery the gestational age and actual birthweight were used to confirm 
position on a normal distribution birthweight centile chart with <10th centile 
defined as SGA. Subjects were classified into 2 groups based on birthweight, 23 
mothers with SGA infants (birthweight <10th centile) and 23 mothers with AGA 
infants (birthweight >10th centile).
Six weeks after delivery, patients attended for a follow up visit, and were 
instructed to fast for at least 12 hours. Weight and blood pressure were measured, 
and the method o f infant feeding was documented. Blood was then drawn in the 
supine position from a vein in the antecubital fossa. Sixty ml o f blood was drawn 
into lithium-heparin coated bottles for EPC culture. Blood was also drawn for 
conventional cardiovascular risk markers and adiponectin. Patients were 
observed until well enough to leave the unit.
Ultrasonography
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All subjects underwent detailed high resolution doppler ultrasonography at 
28weeks and at least every 4 weeks after that until delivery. Fetal well-being and 
biometry were measured, and blood flow through the umbilical cord was 
assessed with colour flow doppler. All scans were performed in the department, 
by a doctor or specialist midwife ultrasonographer.
4.2 Laboratory Methods
Unless stated otherwise, cell culture reagents were obtained from Gibco BRL 
(Karlsruhe, Germany). All other chemical reagents were purchased from Sigma- 
Aldrich (Dublin, Ireland) and were o f the highest purity available.
4.2.1 EPC isolation and culture
Blood was brought to the laboratory as soon as possible after sampling meaning 
that all samples were processed within 45 minutes o f blood draw.
Sixty millilitres o f blood for EPC isolation was decanted into 50 ml tubes, and 
diluted 1:1 in HBSS (Hanks Balanced Salt Solution). 30 mis o f the blood/HBSS 
mixture was then gently layered onto 20mls o f Ficoll-Paque Plus (GE Healthcare 
Life Sciences, UK) for density gradient centrifugation. After centrifuging at 1800 
rpm for 30 minutes the mononuclear/buffy coat layer was removed with Pasteur 
pipettes and transferred into 50 ml tubes. The solution was made up to 50 mis 
with Phosphate Buffered Saline (PBS), and centrifuged for 10 minutes at 1600 
rpm. The supernatant was then removed and discarded, and the pellet re­
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suspended in 5 mis o f Red Cell Lysis buffer, with pipette mixing for 30 seconds 
to lyse contaminating red blood cells. The tube was then centrifuged for 10 
minutes at 1600 rpm. The supernatant was removed, the pellet was re-suspended 
in 5 mis Phosphate Buffered Saline, and spun again for 10 minutes. This step was 
repeated twice. The final pellet was then resuspended in Endothelial Basal 
Medium-2 (EBM-2, Lonza Walkersville, Inc. MD, USA) supplemented with 5% 
fetal-bovine serum, human VEGF-A, human fibroblast growth factor-2, human 
epidermal growth factor, insulin-like growth factor-1, ascorbic acid, 
hydrocortisone and heparin (EGM-2 bulletkit, Lonza Walkersville, Inc. MD, 
USA). 10 x 106 cells were plated in each well o f a fibronectin-coated 6 well plate 
in 2 mis o f EGM-2.
The plates had been pre-coated with fibronectin as follows: Each well was 
covered in 600 microlitres o f HBSS. 25 microlitres o f Human Fibronectin 0.1% 
solution was added to the HBSS and the mixture allowed to dry. The supernatant 
was decanted to aid drying.
Cells were placed in an incubator at 37°C in humidified 5% C 0 2. After 4 days in 
culture non-adherent cells were removed, new media applied, and the culture 
maintained through day 7. Adherent cells at day 7 underwent analysis.
For EPC characterisation at day 7, 10 microlitres o f l,19-dioctadecyl-3,3,3',3'- 
tetramethylindocarbocyanine labelled acetylated low-density lipoprotein (Dil- 
acLDL, Invitrogen Corporation, CA, USA) was added to 1 ml o f media, and cells 
replaced in the incubator for 5 hours. Cells were then washed with PBS, media
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replaced, and 10 microlitres o f fluorescein isothiocyanate-labelled lectin from 
U lex Europaeus  (FITC-Lectin, Sigma-Aldrich, MO, USA) was added, and cells 
replaced in the incubator for a further 4 hours. Cells were then washed with PBS, 
and viewed under fluorescent microscopy. Cells dual-staining for dil-acLDL and 
lectin were considered EPCs.
The number of EPCs was determined by counting 12 random high-power (400x) 
microscope fields per subject’s day 7 cells. The counting was performed by a 
single investigator, who was blinded to the identity and status o f the EPC donor.
4.2.2 EPC functional studies
After counting on day 7, EPCs were carefully detached using EDTA (Enzyme- 
Free Cell Dissociation Buffer, Invitrogen Corporation, CA, USA) and re­
suspended in serum free media (EBM-2). These cells then underwent adhesion 
and migration studies as below.
4.2.2.1 EPC Migration Study
Adapted from Choi et al [116] and Soncin et al [117]. EPC migratory function, 
which is essential for angiogenesis, was examined using a modified Boyden 
chamber technique (BD Biocoat Growth Factor Reduced Matrigel Invasion 
Chamber, BD Biosciences, Oxford, UK). The chamber consists o f a 24-well cell 
culture insert with an 8 micrometre pore size PET membrane, uniformly coated 
with Matrigel matrix (Figure 1). The matrix provides a barrier to non-invasive
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cells while presenting an appropriate protein structure for invading cells to 
penetrate before passing through the membrane. EPCs at a concentration o f 5 x 
104 in 500 microlitres VEGF-free EGM-2 were added to upper part o f the 
chamber. 750 microlitres o f media was added to the lower part o f the chamber, 
and VEGF was used as a chemoattractant. The stimulated wells contained EGM- 
2 (which contains VEGF) and the control wells contained VEGF-free EGM-2. 
After 24 hours incubation at 37°C in humidified 5% CO2, the upper side o f the 
filter was scrubbed and the filter was fixed in 100% methanol. For quantification, 
cells were stained with an eosin and methylene blue stain (Speedy-Diff Complete 
Kit, Clin-Tech Ltd, Guilford, UK). The membrane was removed and mounted on 
a slide. Cells migrating into the lower chamber were counted manually in 12 
random high power (400x) microscope fields by a single investigator, who was 
blinded to the identity and status o f the EPC donor. A  migration coefficient was 
calculated by dividing the number o f migrated cells in the stimulated chambers 
by the number migrated in the control chambers (for example a coefficient of 1 
means that there were the same number o f cells in both chambers, and that there 
was no increase in migration towards VEGF). Assays were run in duplicates.
4.2.2.2 EPC Adhesion Study
EPC adhesion to a matrix molecule was assessed using fibronectin-coated plates, 
adapted from Tepper et al [54], 96 well plates (Nunc Denmark) were coated with 
fibronectin as follows: Each well was covered in 50 microlitres o f HBSS. 2 
microlitres of Human Fibronectin 0.1% solution was added to the HBSS and the 
mixture was allowed to dry. Wells were blocked for 2 hours with 1% Bovine
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Serum Albumin (BSA) in PBS. Wells were then rinsed with 300 microlitres of 
PBS. 5 x 104 cells in 100 microlitres Serum Free Media were added to each well 
and allowed to attach for 1 hour at 37°C in humidified 5% CO2 . After incubation, 
non-adherent cells were washed off with 300 microlitres PBS. Cells were fixed 
with 200 microlitres 10% formaldehyde for 5 minutes. The centre of each well 
was photographed at lOOx magnification for future counting. Adherent cells were 
stained with 0.1% Crystal Violet for 5 minutes. Wells were rinsed twice with 300 
microlitres PBS and allowed to dry briefly. 100 microlitres 100% methanol was 
added to elute the stain from the cells. Attached cells were quantified by 
analysing the optical density of the solution at a wavelength of 595nm with a 
microtitre plate reader (Wallac Victor 2 1420 Multi-label counter). The 
background optical density was subtracted and each data point was the average 
of 5 wells. The optical density is expressed in Fluorescence Units (FU), with a 
lower reading indicating a lower number of adherent cells. (Figure 2)
4.2.3 Additional Confirmation of EPC Phenotype
In addition to dual staining with FITC-Lectin and Dil-acLDL under fluorescent 
microscopy, we performed other experiments to confirm EPC phenotype in our 
culture conditions. Expression of the stem cell and endothelial antibodies CD34 
and anti-human kinase insert domain receptor-1 (KDR, otherwise known as 
VEGFR-2, Vascular Endothelial Growth Factor Receptor-2), typical of EPC, 
cells were analysed with western blot and laser scanning cytometry.
4 . 2 . 3 . 1  W e s t e r n  B l o t
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Cells were taken from EPC culture described above at days 0, 4 and 7, and 
expression of CD34 and KDR were analysed using a western blot.
4.2.3.1.1 Sample Collection
Cells (1 x 107) were taken at day zero (ie cells purified from the mononuclear 
layer prior to plating), and at days 4 and 7 one well was scraped with a cell 
scraper and the contents collected. Samples were centrifuged at 1500rpm for 
5min, the supernatant was removed and the pellet re-suspended in lOOul RIPA 
buffer (RIPA buffer: 400ul tris(hydroxy methyl)aminomethane (tris) (pH 7.4), 
lOOul EGDT, 200ul EDTA, 2ul Na3V04, 25ul NaF, 0.106g sodium 
pyrophosphate, lOOul triton, 20ul NP-40, 4ul PMSF in 20ml dH20). After lOmin 
the solution was centrifuged for lOmin at 13000rpm, 4°C, the debris was 
removed and the supernatant was frozen at -20°C.
4.2.3.1.2 SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel 
electrophoresis)
As the proteins for detection were 150 kDa (KDR) and 109 kDa (CD34), a 10% 
separating gel was prepared. 9.6ml deionised water (dH20), 6ml 1.5M Tris-HCl 
(pH 8.9), 8ml protogel (10% acrylamide, 0.9% bis-acrylamide stock solution), 
0.24ml 10% SDS, 0.15ml 10% ammonium persulphate (APS), 0.006ml 
Tetramethylethylenediamine (TEMED) was added to a 50ml tube. The chambers 
were prepared, filled with separating gel and overlayed with 200 microlitres 
isopropanol to ensure and even setting of the gel. Chambers were left to set for 
30 minutes and the isopropanol was washed out with distilled water. Stacking gel 
was prepared (3.4ml H20, 0.83ml 30% protogel, 0.63ml 0.5M Tris-HCl (pH
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6.8), 0.05ml 10% SDS, 0.05ml APS, 0.005ml TEMED) and overlayed onto 
separating gel with a comb. After chamber had set the silicone gasket and comb 
were removed and the chamber was inserted into the electrophoresis chamber.
Sample buffer was prepared (2g SDS, 1.54g DDT, 2ml 0.2% bromophenol blue 
and 50% sucrose, 0.5ml EDTA (pH 7.0), 2.1ml tris-HCl (pH 6.7) in 10ml dH20) 
and 5ul sample buffer was added to both 5ul and 1 Oul samples from day 0, 4 and
7. Eppendorf tubes were heated at 99°C for lOmin and then centrifuged for 
lOsec.
Samples were added to the electrophoresis chamber, along with myosin blue 
marker (250kDa) and phosphorylase orange marker (148kDa), and lOOv was 
applied until elecrophoresis was complete (approx 75min). The gel was then cut 
off the glass and placed in coomassie stain overnight. The gel was then placed in 
a de-stain solution (25% methanol, 10% acetic acid and 65% dH20) and the 
intensity of the bands was measured. The intensity of the bands was 29000, 
22000 and 7000 for days 0, 4 and 7 respectively. In order to standardise the 
protein levels in each of the samples, the SDS-PAGE was repeated with 3.8ul of 
day 0, 5ul of day 4 and 15.7ul of day 7 samples.
The gel was transferred onto nitrocellulose using transfer buffer (80ml lx 
running buffer and 20ml methanol) for 90min at 150mA, 7 volts. Equal bands 
were visualised with a temporary Ponceau S stain. The nitrocellulose gel was 
placed in blocking solution for lhr (3% powdered milk, 1% BSA in TBS) (TBS 
= 11.69g NaCl, 6.06g trizma base in 11 dH20 at pH 7.0).
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lOOul KDR goat polyclonal antibody added to 20ml blocking solution, and the 
blot was left in this on rocking tray at 4°C overnight. The blot was rinsed for 
,30min with PBS tween, and this step was repeated. The blot was then placed in 
25ul donkey anti-goat IgG-HRP in 25ml blocking solution for lhr. After washing 
in PBS tween, PICO fluorescence (SuperSignal West Pico Chemiluminescent 
Substrate, Thermo Scientific, Rockford IL, USA) was used for the western blot.
The blot was washed in PBS tween and the above steps were repeated using 
monoclonal CD34 mouse primary antibody, and anti-mouse IgG-HRP secondary 
antibody. After washing, PICO fluorescence and Femto maximum sensitivity 
substrate (SuperSignal West Femto Substrate, Thermo Scientific, Rockford IL, 
USA) was added.
To ensure equal loading, GAPDH rabbit polyclonal IgG primary antibodies, and 
anti-rabbit IgG-HRP secondary antibodies were used in the same manner 
described for CD34 and KDR antibodies.
4.2.3.2 Laser-scanning Cytometry
Cells were grown directly on chamber slides to allow quantification of 
expression of CD34 and KDR with laser scanning cytometry.
Chamber slides were pre-coated with fibronectin as follows: Each well was 
covered in 160 microlitres of HBSS. 10 microlitres of Human Fibronectin 0.1%
8 0
solution was added to the HBSS and the mixture allowed to dry. 1 x 105 cells in 
lml EGM-2 were added to each well, and cells were cultured up to day 7, with a 
change of media on day 4, in an identical manner to the method described above.
On day 7 non-adherent cells were washed off with PBS. Adherent cells were 
fixed with methanol 100% for 10 minutes and then rinsed with PBS. Wells were 
then blocked with 2% BSA in PBS for 15 minutes at room temperature. Primary 
antibodies used were goat anti-human KDR and mouse anti-human CD34. 
200microlitres of each primary antibody was added to designated wells for 
30min at 4°C in a humidified chamber. The blocking solution was left on control 
wells. All wells were then rinsed with PBS and labelled with secondary antibody 
for 30min at 4°C in a humidified chamber. Secondary antibodies were 
fluorescein isothiocyanate (FITC) conjugated donkey anti-goat and bovine anti­
mouse. Wells were washed with PBS and a 1:1 mix of counter-stain (PI, 
propidium iodide 1:1000 in PBS) and permeabilising solution (0.1% sodium 
citrate and 0.1% triton x-100 in PBS) was added to each well for 10 minutes at 
room temperature in the dark. Wells were washed x3 with PBS, allowed to dry 
and then chambers were removed from the slides. Fluorescence was measured at 
588nm for nucleolus (PI) and 530nm for FITC labelled antibodies and quantified 
with CompuCyte software (Westwood, MA, USA). Six areas of each slide were 
analysed, and 3000 cells were counted in each area. Mean FITC expression was 
calculated and the control wells were compared to those that had been treated 
with the primary antibodies.
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4 . 2 . 4  M e a s u r e m e n t  o f  c a r d i o v a s c u l a r  r i s k  f a c t o r s
At the same time as sampling for EPC culture, peripheral blood was drawn from 
the patients after a 12 hour fast. Lipids, glucose, insulin and glycosylated 
haemoglobin were measured in the local laboratory (Fusion 51 (Johnson & 
Johnson, USA) and HA/8160 (Menarini Diagnostics, UK)).
Blood in Li-heparin bottles for adiponectin levels was immediately separated by 
centrifugation for 10 minutes at 1500 rpm 4°C. The plasma supernatant was 
removed, placed in cryovials using a transfer pipette, and stored at -80°C until 
assay.
The Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) was used 
to estimate steady state beta cell function (%B) and insulin sensitivity (%S) as a 
percentage of a normal reference population [118]. HOMA-IR was calculated 
using fasting serum insulin and fasting plasma glucose using the HOMA2 
calculator (Diabetes Trials Unit, University of Oxford).
4.2.5 Measurement of adiponectin
4.2.5.1 Introduction
The assays were performed at the same time using a commercially available 
enzyme-linked immunosorbent assay (ELISA), (Millipore, MA, USA). This 
assay is a Sandwich ELISA based on the following sequence:
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1) Concurrent capture of Human Adiponectin molecules from samples to the 
wells of a microtiter plate coated with a monoclonal anti-human adiponectin 
antibodies, and binding of a second biotinylated monoclonal anti-human 
antibody to the captured molecules.
2) Washing of unbound materials from samples.
3) Binding of streptavidin-horseradish peroxidise conjugate to the immobilised 
biotinylated antibodies.
4) Washing of excess of free enzyme conjugates.
5) Quantification of immobilized antibody-enzyme conjugates by monitoring 
horseradish peroxidase activities in the presence of the substrate 3,3’, 5,5’- 
tetramethylbenzidine.
The enzyme activity is measured spectrophotometrically by the increased 
absorbance at 450 nm -  590nm after acidification of formed products. Since the 
increase in absorbance is directly proportional to the amount of captured Human 
Adiponectin in the unknown sample, the latter can be derived by interpolation 
from a reference curve generated in the same assay with reference standards of 
known concentrations of Human Adiponectin.
4.2.5.2 Methods
At the time of delivery, 10ml cord blood was collected into EDTA bottles from 
attached umbilical cords of fresh placenta by gravity flow. Cord blood was 
immediately separated by centrifugation for 10 minutes at 1500rpm and the 
resulting plasma was frozen at -80°C until assay. At the time of the 6 week visit, 
2 mis of maternal plasma was immediately separated and stored at -80°C until
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assay for Adiponectin. The assays were all performed at the same time, stored 
plasma samples were allowed to come to room temperature and assays were 
performed according to the manufacturer’s instructions (see Figure 3).
Human adiponectin standard was prepared and serial dilutions were performed, 
giving 7 concentrations (100, 50, 25, 12.5, 6.25, 3.125, 1.56 ng/mL). 2 quality 
control vials were also prepared, and stored samples were allowed to come to 
room temperature prior to assay, and all assays were performed in duplicate.
The microtitre assay plate was washed 3 times with wash buffer, and residual 
wash buffer was removed. 60ul assay buffer was added to all wells, and 20ul to 
blank wells. 20 ul sample (standard, quality control or sample) was then added to 
appropriate wells. Then 20ul detection antibody was added to all wells and the 
plate was incubated at room temperature for 2 hours on a plate shaker at 500rpm. 
Residual solutions were decanted and wells were washed 3 times with 300ul 
wash buffer. lOOul enzyme solution was then added to each well, the plates were 
covered and incubated for 30 minutes as before. Solutions were decanted and 
wells were washed 5 times with 300ul wash buffer. lOOul substrate solution was 
added to each well and incubated for 5-10 minutes until blue colour was seen 
forming in the wells. lOOul stop solution was added and plates were shaken to 
ensure adequate mixing. Any air bubbles were removed and plates were read on 
a microtitre plate reader at 450nm and 590nm. A standard curve was calculated 
for each plate with the results from the human adiponectin standard. The results 
of unknown samples were then calculated using a sigmoidal 5 parameter logistic 
equation. Quality control samples were used to check the quality control range.
8 4
4 . 3  S a m p l e  s i z e  a n d  s t a t i s t i c a l  a n a l y s i s
The primary analysis was to compare EPC number and function, adiponectin and 
conventional cardiovascular risk markers in mothers of AGA and SGA infants. 
Based on a sample size of 46 participants, the study had sufficient power (80%) 
to detect a difference in EPC count of at least 25 in AGA and SGA infants at the 
5% level of significance.
Continuous variables were described using the median and interquartile range 
while categorical variables were presented as frequency tabulations. The SGA 
and AGA groups were compared using non-parametric statistical methods 
(Fisher’s Exact test for binary data, Wilcoxon rank sum test for continuous data, 
and Spearman’s rank correlation coefficient) in order to alleviate the influence of 
possible non-normality or outlying values. Continuous variables among the three 
groups were analysed by Jonckheere-Terpstra test for ordered hypothesis.
In order to assess the impact of possible confounding variables, a multivariate 
analysis was performed using a forward stepwise logistic regression, as 
implemented in SPSS (using the default 5% level of significance for variable 
entry and 10% probability for variable removal). The Bonferroni adjustment was 
used to adjust p-values for multiple comparisons with statistical significance set 
at the nominal 5% level. The statistical software programme SPSS Version 18 
was used for statistical analysis.
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5.1 Confirmation of EPC phenotype and measurement of adiponectin
In our culture conditions all adherent cells at day 7 were dual-positive for dil- 
acLDL and lectin, therefore staining was not performed routinely. (Figure 4)
5.1.1 Western Blot
On GAPDH staining there was equal loading of protein in all three samples at 
37kDa. On staining for KDR, protein bands were seen at 150 kDa, increasing in 
intensity from day 0 to 4 to 7. On staining for CD34, no band was seen using 
PICO fluorescence, so Femto maximum sensitivity substrate was added and a 
band was seen at 1 lOkDa on the day 7 sample only. These findings correspond 
with an increasing expression of KDR as cells progressed through culture, and at 
day 7 cells expressed both KDR and CD34 (Western Blot Images, figure 5).
5.1.2 Laser-scanning Cytometry
We found significantly higher expression of both CD34 and KDR than control in 
day 7 cells; mean CD34 vs control (141164 vs 118608, p <0.01), mean KDR vs 
control (348448 vs 186198, p<0.01), Table 1. The results confirm dual 
expression of CD34 and KDR in day 7 EPCs in our culture conditions.
5.1.3 Adiponectin ELIS A
A standard curve was calculated for each plate with the results from the human 
adiponectin standard (Figure 6). The results of unknown samples were then
C h a p t e r  5 .  R e s u l t s
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calculated using a sigmoidal 5 parameter logistic equation. Quality control values 
were confirmed to fall within the quality control range.
5.2 Patient characteristics
There were 23 mothers in the Appropriate for Gestational Age (AGA) group who 
delivered babies with birth weights between the 10th and 90th centile, and 23 
mothers in the Small for Gestational Age (SGA) group with babies under the 
10th centile for birth weight. Table 2 details the baseline characteristics for the 
two groups.
There was a trend towards taller and heavier mothers in the control group but the 
difference was not statistically significant and there was no difference in BMI. 
Both maternal ages and paternal ages were marginally lower in the SGA group as 
compared to the AGA group but not statistically significant. In addition, the SGA 
and AGA groups had comparable parity and ethnicity.
There were five patients with pregnancy induced hypertension or preeclampsia in 
the study population (2 vs. 3 patients in the SGA and AGA groups, respectively, 
p=0.639.) Two patients had a family history of ischaemic heart disease, both 
appearing in the SGA group but too few to be statistically significant. There were 
significantly more patients with an abnormal umbilical artery doppler ultrasound 
in the SGA group compared to the AGA group (4 vs. 0, p=0.038).
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There was a borderline non-significant higher median diastolic blood pressure at 
30 weeks gestation in the SGA group compared to the control group (70 [68-79] 
vs. 70 [60-70] mmHg, p = 0.052), and when patients returned for the post-partum 
visit (table 4) there was no difference in blood pressure between the two groups.
As expected, birth weight was lower in the SGA group compared to AG A group 
(2.34 [2.13-2.65] vs. 3.6 [3.17-3.85] Kg, p<0.001), and when adjusted for 
gestational age the median birth centiles in SGA versus AGA groups were 2nd 
[0.5-3.5] vs. 58th [33.5-76] (p<0.001, Table 3). The rate of caesarean section and 
the gender of the infant were similar in the two groups.
Table 4 details results of testing at 6 weeks post partum. Fasting triglyceride 
levels were higher in the SGA group than the control group (0.98 [0.81-1.38] vs
0.78 [0.66-0.91] mmol/1, p=0.006), but there were no other significant 
differences in the lipid profile or cardiovascular risk markers.
5.3 EPC number and function
Median EPC count was significantly lower (294 [236-338] vs. 367 [331-415], 
p=0.005), Table 5 and Figures7-9, and EPC migratory capability was reduced 
(migration index 0.91 [0.86-1] vs. 1.59 [1.22-1.81], p<0.001) in SGA compared 
to AGA, but there was no statistically significant difference in EPC adhesion 
(0.221 [0.179-0.296] vs. 0.284 [0.214-0.4] FU, p=0.257). Using spearman’s rank 
correlation coefficient (r) we found moderate correlation between birth centile 
and EPC number (r=0.493, p=0.001) and EPC migration (r=0.682, p<0.001), but
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no correlation with EPC adhesion (r=0.281, p=0.088). Correlations were also 
seen between birth weight and EPC number and migration, but these were 
slightly less strong than those seen with birth centile (r=0.486 and 0.638 for EPC 
number and migration respectively), Figures 10-12. There was a moderate 
negative correlation between triglycerides and EPC migration (r=-0.475, 
p=0.001), Figure 13.
5.4 Adiponectin
There was no significant difference in maternal serum adiponectin levels 
between the two groups, however median umbilical cord blood adiponectin was 
lower in the SGA group (55.2 [47-65] vs. 70.4 [54.2-76.6] ng/ml, p=0.033), 
Table 6 and Figure 14. Analysis using Spearman’s rank correlation coefficient 
indicated a linear relationship between birth weight and umbilical cord blood 
adiponectin, with a moderate correlation (r = 0.475, p=0.005), Figure 15. There 
was a weak borderline non-significant correlation between maternal and cord 
blood adiponectin (r = 0.34, p=0.049).
5.5 Multivariate model
We performed a multivariate analysis to assess possible confounding variables 
(Age, Parity, Breast feeding, BMI, BP (during and after pregnancy), Glucose, 
HbAlc, Cholesterol, HDL, LDL, Triglycerides, Adiponectin), Table 7. A 
stepwise logistic regression analysis showed that only EPC measures (count and 
migration) remain in the models. Therefore other markers such as triglycerides
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and blood pressure are not as strong predictors, nor do they improve the 
prediction of SGA/AGA status when added to EPC measures.
5.6 Physiologically small vs. pathologically small
We aimed to differentiate between infants that were physiologically or 
constitutionally small and those that had a pathological cause of growth 
restriction.
The American Society for The American College of Obstetricians and 
Gynaecologists defines intra-uterine growth restriction (IUGR) as a fetus with an 
estimated weight below the 10th percentile for gestational age [119]. However 
not all fetuses weighing less than the 10th centile for gestational age are at risk for 
adverse outcomes, and may just be constitutionally small. One study identified a 
false positive rate of 74% for the diagnosis of IUGR using <10th centile alone 
[120] - in other words the majority of those labelled as IUGR may in fact be 
normal or constitutionally SGA and therefore not at risk of poor fetal or neonatal 
outcomes. Some groups have suggested using a cut-off of <3rd centile to identify 
genuine IUGR fetuses [121], and others have suggested the use of growth charts 
that are customised to physiological pregnancy variables such as maternal height, 
weight, parity and ethnic group [122].
Then pattern of growth restriction can also give clues as to the significance of 
any deficiencies identified, and IUGR can be classified as symmetric and
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asymmetric. Symmetric growth restriction implies a fetus whose entire body is 
proportionally small. Asymmetric growth restriction implies a fetus who is 
undernourished and is directing most of its energy to maintaining growth of vital 
organs, such as the brain and heart, at the expense of the liver, muscle and fat. 
This type of growth restriction is usually the result of placental insufficiency 
[123].
For the purpose of identifying genuine pathologically small babies, the SGA 
group was further divided into 2 groups: Constitutionally Small for Gestational 
Age (CSGA) and IUGR. IUGR was defined as having at least 2 out of the 
following 3 parameters:
1. Asymmetric growth or abnormal progression through EFW centile 
chart
- 2. Abnormal doppler ultrasound of placental artery (absent or reversed
end-diastolic flow)
3. Histological analysis of placenta consistent with utero-placental 
insufficiency.
These three parameters were assessed by independent investigators who were 
blinded to the status of the patients as follows: Anonymised ultrasound doppler 
images and measurements (performed by midwife ultrasonographers in a single 
unit) were presented to an independent consultant obstetrician who determined if 
there was abnormal placental artery blood flow. In a similar way, anonymised 
growth centile charts were examined for normality by an independent consultant
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obstetrician. A consultant pathologist who was blinded to the status of the patient 
assessed the placentae for features of placental insufficiency.
There were 18 subjects in the CSGA subgroup and 5 in the IUGR subgroup, and 
the baseline characteristics of these two subgroups compared to the control group 
are shown in Table 8. Categorical variables are presented as n (%) and 
continuous variables median [IQR]. The Jonckheere-Terpstra test for ordered 
hypothesis was used to compare the three groups.
There was no statistically significant difference in BMI, age, paternal age, parity, 
ethnicity or family history of ischaemic heart disease between groups. There was 
a significantly higher median diastolic blood pressure at 30 weeks gestation in 
the IUGR group compared to the AGA and CSGA groups (80 [77-82] vs. 70 [60- 
70] and 70 [66-72] mmHg respectively, p=0.012), but when patients returned for 
the post-partum visit there was no difference in blood pressure between the two 
groups.
Table 9 shows the delivery details of the three groups. Birth weight and birth 
centile were even lower in the IUGR group compared to the AGA and CSGA 
groups (Birth weight 2.1 [1-4.75] vs. 3.6 [3.17-3.85] and 2.45 [2.25-2.7] Kg 
respectively, p<0.001, and birth weight centile <lst [0.1-1] vs. 58th [34-76] and 
2nd [2.02-2.16] respectively, p<0.001).
Table 10 details results of testing at 6 weeks post partum. Although the 
differences were not statistically significant, the IUGR subgroup had higher
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insulin levels and were more insulin resistant then the AGA and CSGA groups 
(Insulin 9.0 [8.8-14.4] vs. 6.3 [5.0-7.8] and 6.9 [5.7-7.8] mU/1 respectively, 
p=0.056, and HOMA-IR 1.2 [1.1-1.8] vs. 0.8 [0.7-1.0] and 0.9 [0.7-1.0] 
respectively, p=0.053). Similarly, there was a significantly higher triglyceride 
level (1.6 [1.2-1.8] vs. 0.8 [0.7-0.9] and 0.9[0.8-1.2] mmol/1 respectively, 
p=0.001). There were no other significant differences in the lipid profile or 
cardiovascular risk markers.
When comparing EPC number and function between the three groups, we found 
a progressive decline in EPC count from the AGA to CSGA to IUGR groups 
(367 [331-415] vs. 316 [244-349] vs. 276 [206-297], p=0.003). The IUGR group 
had similar defects in EPC migration as the CSGA group (Migration coefficients 
for AGA, CSGA and IUGR: 1.59 [1.22-1.81], 0.90 [0.85-1.0] and 0.91 [0.88-
0.99] respectively, p<0.001). There was no significant difference in EPC 
adhesion between the three groups (Table 11).
There was no significant difference in umbilical cord blood or maternal 
adiponectin between the three groups (Table 12 and Figure 15).
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C h a p t e r  6 .  D i s c u s s i o n
The link between maternal cardiovascular disease and offspring birth weight is a 
fascinating one, and to date, remains unexplained. EPCs are thought to play a key 
role in vasculogenesis. Since their discovery in 1997 [5] EPCs have been found 
to be associated with a wide variety of disease states and are thought to 
accurately reflect cardiovascular risk [8]. Our study produced a number of 
interesting results and supports our hypothesis that EPC pathology is an 
important determinant of deficient placentation leading to low birth weight and 
increased maternal cardiovascular risk.
We report a 20% decline in EPC number in mothers of babies bom small for 
gestational age compared to a control group of mothers giving birth to normal 
size babies. The migratory capacity of isolated EPCs was also significantly 
impaired in the SGA group, with the EPCs from this group showing no migratory 
response to VEGF, with a net reduction in migration of 68%. Although there was 
a trend towards a reduced adhesive capacity of the cells in the SGA group, there 
was no statistically significant decline in the ability of EPCs from the SGA group 
to adhere to fibronectin in vitro.
The decline in EPC number and function which we have demonstrated may 
account for the expected increase in cardiovascular risk between the two groups 
studied. The median birth weight difference in our groups was 1260g, and the
6 . 1  E P C  n u m b e r  a n d  f u n c t i o n
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median birth weight centile was over 2 standard deviations below normal in our 
SGA group. The meta-analysis by Davey Smith reported that a 1SD (approx 
500g) decline in birth weight is associated with a 25% increase in future maternal 
cardiovascular mortality [79]. Extrapolating these data to our subjects would 
suggest a 50% increase in future cardiovascular mortality in our SGA group. 
Previous studies have shown a 10% reduction in EPC number in smokers [14], a 
34% reduction in patients with metabolic syndrome [12], a 69% reduction in type
2 diabetes, [124] and a 47% reduction in haemodialysis patients [125]. The 20% 
decline in EPC numbers along with the 68% decline in EPC migratory capacity 
that we discovered in our SGA subjects, therefore, could account for an increased 
cardiovascular risk approximating that predicted.
There was no significant difference in maternal age, body mass index or family 
history of cardiovascular disease in the two groups at baseline, and we found no 
significant difference in maternal fasting glucose, insulin, glycosylated 
haemoglobin, low and high density lipoprotein or HOMA-IR at 6 weeks post­
partum. Fasting triglyceride levels were significantly higher in the SGA group 
(p=0.006), however, and we found a borderline non-significant difference in 
diastolic blood pressure at 30 weeks gestation, although the latter difference had 
resolved by the time of the 6 week post-partum visit. When adjusting for multiple 
comparisons the difference in triglycerides was not statistically significant 
(Bonferroni p value = 0.06) and therefore the observed difference could be due to 
a chance finding in our study population.
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Hypertriglyceridaemia is an independent risk factor for coronary heart disease, 
and epidemiological data suggest that a 1 mmol/1 increase in triglycerides is 
associated with a relative risk of cardiovascular disease of 1.37 (95% Cl, 1.13 to 
1.66) [126]. Extrapolating this to our data, the median difference of 0.2mmol/l in 
triglyceride levels between the SGA and AGA groups could account for a 7.4% 
difference in cardiovascular risk. Although this cannot be ignored, it is unlikely 
to be the sole explanation for the predicted increase in cardiovascular risk in 
mothers of low-birth-weight babies. Similarly, the difference in diastolic blood 
pressure during pregnancy was not statistically significant, and there was no 
difference in rates of pre-eclampsia or gestational hypertension between the two 
groups.
The hazard ratio for future cardiovascular disease in women who have had a 
maternal placental syndrome (pre-eclampsia, gestational hypertension, placental 
abruption, or placental infarction) is 2.0 (Cl 1.7-2.2) [68], Therefore a difference 
in the incidence of these conditions, or indeed a difference in blood pressure 
could potentially explain a difference in predicted cardiovascular mortality 
between the two groups. However, the difference in diastolic blood pressure 
during pregnancy in our groups was not statistically significant, had resolved 
completely by the time of the 6 week visit, and there were similar rates of 
maternal placental syndrome and true hypertensive disorders in our 2 groups, 
making it unlikely that the blood pressure difference found could contribute to an 
increase in cardiovascular risk.
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Hill et al [8] found that when compared with subjects with high EPC numbers, 
those with low EPC numbers had higher triglyceride levels (2.04 +/- 0.41 vs.
1.26 +/- 0.18, p=0.09) and were more likely to have hypertension (53 vs 7% of 
subjects diagnosed with hypertension, p=0.01). In regression analysis, Vasa et al 
[13] found that hypertension was an independent predictor for impaired EPC 
migration (p=0.043), but not reduced EPC number (p=0.174). In a similar 
regression analysis of their data on EPCs in metabolic syndrome, Jialal et al [12] 
found that elevated serum triglyceride predicted reduced circulating EPC 
number. However, opposite findings were shown in a larger study examining 
EPC number in 571 subjects, by Xiao et al [127]. Subjects with low EPC 
numbers had lower median serum triglycerides than subjects with high EPC 
numbers (1.26 (1.03-1.70) vs. 1.40 (1.04-2.04) mmol/1, p=0.001), and after 
removing subjects that were taking medications the positive correlation 
remained. The authors also found a surprising positive correlation between 
Framingham risk score and EPC number. The evidence is clearly conflicting and, 
to our knowledge, there have been no studies examining EPC number and 
function in selected patients with hypertriglyceridaemia.
We found a moderate negative correlation between serum triglycerides and EPC 
migration (r=-0.475) in our cohort, however after adjustment for triglycerides 
and blood pressure by stepwise multivariate logistic regression analysis, EPC 
migration remains a strongly significant predictor of SGA/AGA status (p<0.001). 
Therefore triglycerides could explain some of the EPC differences, but the 
adjustment for multiple comparisons and adjustment in logistic regression imply
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that they do not explain all of the differences in EPC number or function, or 
predicted future cardiovascular risk between the two groups.
The higher number of subjects with abnormal umbilical cord blood flow on 
ultrasound doppler in the SGA group supports our contention that the defects in 
EPC number and migratory ability which we have identified in our SGA group 
may be responsible for deficient development of the placental vasculature 
leading to low birthweight. Larger studies will be required to determine if 
mothers with abnormal umbilical artery blood flow have reduced EPC number 
or function and a greater future cardiovascular risk than those with normal 
ultrasound doppler.
6.2 IUGR vs. SGA
We had aimed to recruit 20 subjects in each group, but despite 18 months of 
active recruiting, we only managed to recruit 5 non-smoking healthy mothers of 
IUGR babies that did not have growth restriction due to disease or chromosomal 
abnormality. However, the analysis of the IUGR group revealed some interesting 
findings, despite the small numbers.
There was a trend toward being younger and having a lower BMI, although the 
differences did not reach statistical significance. Despite this, the IUGR subgroup 
appears to have a much higher cardiovascular risk, in that diastolic blood 
pressure during pregnancy was significantly higher, and there was a non­
significant higher blood pressure at the follow up visit. The difference in
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triglycerides observed between the original AG A and SGA groups was now 
more pronounced in the IUGR group vs. the AGA group.
Again, despite the fact that the IUGR group trended to be younger and thinner, 
we found a trend towards higher levels in insulin resistance and LDL cholesterol, 
although the differences did not reach statistical significance. The lack of 
statistical significance observed may be due to our small sample size.
The mothers in the IUGR subgroup delivered even smaller babies even earlier 
than both the AGA and CSGA groups. As regards EPC number and function 
between the three groups, we found a progressive step-wise decline in EPC count 
from the AGA to CSGA to IUGR groups, the IUGR had similar defects in 
migration as the CSGA group, and there were no differences in adhesion. As 
with the differences in blood pressure and triglycerides, the differences in EPC 
number and migratory ability are interesting. Given the fact that the IUGR group 
trended to be younger with lower BMIs, if anything one could have postulated 
that they would have improved EPC number and function.
The IUGR group by definition were growth restricted due to placental 
insufficiency, and the fact that we found reduced EPC number and function in 
this group supports our hypothesis that EPCs may play a role in reduced 
placental angiogenesis and vascularisation, and furthermore that EPC pathology 
may be linked to the increase in future maternal cardiovascular risk.
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6 . 3  S i g n i f i c a n c e  o f  o u r  f i n d i n g s
In their review article, Sipos et al [80] consider the role of the EPC in intra­
uterine growth restriction and future cardiovascular risk in the offspring. They 
postulate that anomalies in either EPC number or EPC recruitment to the early 
placenta may impair formation of normal placental vessels and influence the 
embryonic endothelium. They also postulate that EPC functional irregularities 
could impact on the maternal side, affecting uterine vessels, restricting or 
attenuating intrauterine blood flow and thus perpetuating placental disease. These 
functional irregularities (namely EPC number, mobilisation and recruitment) 
could possibly result from hypoxia or oxidative stress, and the authors comment 
that given these possibilities, further research is warranted. We have shown a 
defect in both EPC number and migratory capacity, with no difference in EPC 
adhesion. These EPC anomalies may explain the increase in predicted 
cardiovascular risk in not only the child, but also in the mother.
When one considers the maternal long term implications after maternal placental 
syndrome, IUGR and gestational diabetes, it becomes clear that pregnancy 
represents a unique opportunity to identify women who may be at increased risk 
of chronic diseases later in life [128]. After identification of one of these 
conditions in pregnancy, clinicians should not miss the opportunity to screen for 
cardiovascular risk factors, and to institute lifestyle changes or pharmacological 
intervention to prevent complications in the future. Manten et al [129] followed 
up women with a history of IUGR (defined as a birth weight <5 centile and a 
delivery because of signs of fetal distress before 34 weeks of gestation). They
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found that women with a history of IUGR had higher concentrations of 
cholesterol and showed a tendency to higher BMI, higher triglyceride 
concentrations, and increased insulin resistance as compared with women with a 
history of normal pregnancy. We found similar findings in both our SGA and 
IUGR groups. Therefore, irrespective of our findings in relation to EPCs, our 
study has highlighted the presence of hypertension and dyslipidaemia in mothers 
of both SGA and IUGR infants. Both of these are modifiable risk factors that 
increase the risk of future cardiovascular morbidity and mortality.
6.4 Adiponectin
Adiponectin is the most abundant hormone released by adipocytes, and is 
thought to couple regulation of insulin sensitivity with energy metabolism [109]. 
It has anti-inflammatory, anti-apoptotic and anti-atherogenic properties [93-95], 
Some studies have suggested that adiponectin may provide the link between 
obesity, type 2 diabetes, insulin resistance and cardiovascular disease [82, 88, 
89]. High levels are associated with favourable lipid and glucose metabolism, 
and a reduced risk of cardiovascular events in women [106].
Altered maternal adiponectin levels have been found in women with gestational 
diabetes [110, 111] and preeclampsia [112]. Children who were bom SGA have 
been shown to have lower serum adiponectin and levels are even lower in those 
with postnatal catch-up growth [130]. Results of cord blood adiponectin levels 
have been varying, with some authors reporting lower levels in SGA fetuses 
(defined as >1.5 SD below normal) [131], and others reporting no difference in
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SGA (defined as <2500g) [132]. Mazaki-Tovi et al [113] performed an elegant
• * th  study measuring cord blood in normal and discordant growth restricted (<10
centile with abnormal umbilical cord doppler ulstrasound) twins. They found that
cord blood adiponectin was independently associated with birth weight, with
decreased levels characterising growth-restricted fetuses [113]. The nature of the
twin study eliminated confounding maternal factors and gave weight to the
argument that the lower cord blood adiponectin levels were due to abnormal
placentation and not attributable to genetic disparity. The authors postulate that
the observed reduced adiponectin levels in SGA neonates could be due to
decreased fetal adipose tissue depots and increased fetal exposure to hypoxia,
both of which are features of growth restriction.
We found a significantly lower umbilical cord blood adiponectin in our SGA 
group, with a moderate correlation between birth weight and adiponectin in all 
neonates (r=0.475), Figure 2. There was no difference in maternal adiponectin 
levels between the groups, and there was only a weak correlation between 
maternal and cord blood adiponectin (r=0.34) This confirms the findings of 
previous studies, and provides further evidence that fetal adiponectin levels are 
unlikely to be related to maternal levels.
When analysed in the three groups of AGA, CSGA and IUGR, the differences 
cease to have statistical significance, Table 12 and Figure 14. Although the 
numbers in the IUGR subgroup are small, and the differences are not statistically 
significant, the adiponectin levels appear to increase to a near normal level, 
leading to the possibility that levels may in fact be up-regulated in IUGR.
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However, unlike the other studies examining cord blood adiponectin in SGA 
fetuses mentioned above, the discordant twin study that found a lower level did 
examine pathologically small fetuses with abnormal umbilical cord blood flow. 
Therefore the differences observed in our subgroup may be due to our small 
sample size.
In summary, adiponectin has an important role in the regulation of major 
metabolic pathways and fetal growth, and the data from our two groups provides 
additional evidence to the hypothesis that it may form part of the link between 
low birth weight and future metabolic and cardiovascular complications in later 
life.
6.5 Conclusion
EPCs are crucial to post-natal vasculogenesis and intimately associated with 
cardiovascular risk. Placental insufficiency as a result of deficient placental 
vascularisation may be responsible for maternal placental syndromes including 
low birth weight babies. In this thesis I tested the hypothesis that reduced 
maternal EPC number and/or function may play a role in the processes that lead 
to defective placental development and hence low birthweight in babies, and may 
also provide a unifying explanation for the associated future increased risk of 
cardiovascular disease in mothers of low birthweight babies.
I aimed to investigate the link between EPCs, delivery of a low birthweight baby, 
and risk of future cardiovascular disease in the mother by measuring EPC
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number and function, conventional cardiovascular risk markers, and levels of the 
adipokine adiponectin in mothers of SGA and AGA infants. In addition, maternal 
and cord blood adiponectin measurements were used to further investigate the 
role of adiponectin in birthweight and cardiovascular disease.
I found that giving birth to an SGA infant was associated with lower maternal 
EPC number and reduced EPC migratory function in vitro, and that the IUGR 
subgroup had even lower EPC number and similar defects in EPC migration. 
These results support the hypothesis that EPC pathology may represent the 
hitherto elusive link between utero-placental insufficiency (leading to low birth 
weight) and future risk of cardiovascular disease in the mother.
I also report significantly lower cord blood adiponectin levels in SGA infants 
compared to normal birth weight infants, and a correlation between cord blood 
adiponectin and birth weight, confirming previous reports and potentially 
representing a further mechanism for future cardiovascular disease and insulin 
resistance in later life of the infant.
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Appendix 1 : Patient Information Sheet
The
Rotunda Hospital
R C S I DUBLIN
P a t i e n t  I n f o r m a t i o n  L e a f l e t :
E n d o t h e l i a l  P r o g e n i t o r  C e l l s  i n  M o t h e r s  o f  L o w - b i r t h - w e i g h t  b a b i e s
The blood vessels in the placenta (after-birth) supply nutrition to the growing 
baby in the womb. In some cases, when babies are bom small-for-dates, it can be 
as a result of reduced formation of these blood vessels. Endothelial progenitor 
cells (EPCs) are cells which circulate in the blood and are responsible for 
forming new blood vessels in adults.
We plan to measure numbers of EPCs in the blood of mothers of small-for-dates 
babies, and also numbers of EPCs in umbilical cord blood, to see if a low EPC 
number may influence the formation of blood vessels in the placenta. We also 
hope to measure cholesterol, blood sugar level, hormone levels such as 
adiponectin, and blood pressure, to further evaluate the link between all of these 
factors and blood vessel formation. We hope that the results of the study will 
improve our understanding of the reasons for low-birth weight babies and may 
allow for development of EPC-based treatment in the future to prevent this 
condition. In addition to mothers of small-for-dates babies, we also need to study 
mothers of normal birth weight babies (the control group) in order to compare 
the numbers of EPCs between the two. We therefore plan to perform all of the 
above tests on both groups of mothers and babies.
If you agree to take part in our study, we will perform a detailed ultrasound scan 
of the placenta and placental blood vessels. At delivery a sample of blood will be 
drawn from the umbilical cord. This cord blood shall be analysed for EPC 
number and adiponectin level (a hormone that is associated with low birth 
weight), and shall be discarded after the analysis is complete. We will arrange to 
perform a brief physical examination (checking blood pressure, height and 
weight) at your post-natal visit, and then draw some blood for testing. All of this 
should not take much more than 20 minutes. All of your details will be kept 
confidential. There will be no need for any further visits apart from your usual 
hospital visits.
Participation in this study is entirely voluntary and you may withdraw at any 
time, without giving reason, and without this decision effecting any future 
treatment or medical care.
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O u r  r e s p o n s i b i l i t i e s  a s  i n v e s t i g a t o r s :
If you experience any ill effects as the result of your participation, then we will 
take care of your medical needs. If we discover any medical problems such as 
high blood pressure or cholesterol, this would be discussed with you in detail, 
and you would be offered appropriate treatment and follow up in a specialist 
clinic or with your GP. However we will not be in a position to pay for any 
prescription medication, should it be required.
If there are any new findings during the course of the study that may affect the 
validity of the study or your participation in it, then the findings will be made 
available to you and you will receive the appropriate medical care and advice 
depending on the test results.
C o n f i d e n t i a l i t y :
Only anonymous data, ie. data that do not identify you by name, will be 
collected. Only authorised representatives of the study team will have direct 
access to your personal medical records. All study team representatives and 
medical staff are obliged to maintain confidentiality at all times. The data shall 
be destroyed by shredding and deletion of computer files at the end of the study
F o r  a d d i t i o n a l  i n f o r m a t i o n  n o w  o r  a n y  f u t u r e  t i m e  p l e a s e  c o n t a c t :
Dr. Thomas King, Research Registrar
Connolly Hospital, Blanchardstown, Dublin 15. Phone: 01 646 5756
Dr. John McDermott, Consultant Endocrinologist
Connolly Hospital, Blanchardstown, Dublin 15. Phone: 01 646 5758
Prof. Fergal Malone, Consultant in Obstetrics and Gynaecology 
RCSI Unit, Rotunda Hospital, Dublin 1. Phone: 01 878 6070
14th April 2009
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Appendix 2: Consent Form
R C S I
The
Rotunda HospitalDUBLIN
îhe sTi^ttinitv hospital oí choice
C O N S E N T  F O R M
P r o t o c o l  T i t l e :  Endothelial Progenitor Cells in Mothers of Low-birth-weight 
babies
P l e a s e  t i c k  t h e  a p p r o p r i a t e  a n s w e r .
I  consent to take part in this study. DYes D N o
I confirm that I have read and understood the Patient Information Leaflet 
attached (version 2, 14/4/9), and that I have had ample opportunity to ask 
questions all of which have been satisfactorily answered.
□  Y e s  D N o
I have been given a copy of the Patient Information Leaflet and this Consent 
form for my records.
□  Y e s  D N o
I understand that my participation in this study is entirely v o l u n t a r y  and that 
I may withdraw at any time, without giving reason, and without this decision 
affecting my future treatment or medical care.
□  Y e s  D N o
I understand that my medical records may be viewed by members of the 
research team
□  Y e s  D N o
• I understand that my identity will remain confidential at all times.
□ Y e s  D N o
• I am aware of the potential risks of this study.
□  Y e s  D N o
I consent for umbilical cord blood to be taken at the time of delivery, and for 
blood tests (from myself) at my six week post-natal visit.
□ Y e s  D N o
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• I agree that I will not restrict the use to which the results of this study may be 
put. I give my approval that anonymous data concerning my person may be 
stored or electronically processed for the purpose of scientific research and 
may be used in related or other studies in the future. (This would be subject 
to approval by an independent body which safeguards the welfare and rights 
of people in biomedical research studies - the Rotunda Hospital Ethics 
(Medical Research) Committee.)
□ Y e s  Q N o
• I consent for further follow-up studies
□ Y e s  D N o
Patient
Signature and dated Name in block capitals
T o  b e  c o m p l e t e d  b y  t h e  P r i n c i p a l  I n v e s t i g a t o r  o r  h i s  n o m i n e e .
I the undersigned, have taken the time to fully explain to the above patient the 
nature and purpose of this study in a manner that he/she could understand. I have 
explained the risks involved, as well as the possible benefits and have invited 
him/her to ask questions on any aspect of the study.
Signature, qualifications and date Name in block capitals
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F i g u r e  1 :  M a n u f a c t u r e r ’ s  i l l u s t r a t i o n  o f  M a t r i g e l  i n s e r t  ( M o d i f i e d  B o y d e n  
C h a m b e r )
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Figure 2: EPC Adhesion at 1 hour, light microscopy 400x
F i g  2 a :  B e f o r e  s t a i n i n g
F i g  2 b :  A f t e r  s t a i n i n g  w i t h  0 . 1 %  C r y s t a l  v i o l e t
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Figure 4: Dual staining of EPCs (400x)
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Figure 5: Western Blot Images of cultured cells from Day 0,4 and 7
F ig  5a: G A P D H , K D R  and C D 3 4
GAPDH (37kDa)
KDR (150kDa)
CD34 (11 OkDa)
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Figure 5b: Coomassie stain
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Table 1: Laser scanning cytometry results
M e a n  E x p r e s s i o n  o f  C D 3 4  a n d  K D R  i n  D a y  7  C e l l s  v s .  C o n t r o l  W e l l s
Sample CD34 Control (CD34) KDR Control (KDR)
1 154992 129178 384719 191879
2 155291 124152 349454 193639
3 137226 125175 351302 191558
4 139650 117696 323579 176894
5 140773 104759 369705 181981
6 119052 110690 311931 181237
Mean 141164* 118608 348448* 186198
*p-value <0.01 for CD34 vs. Control and for KDR vs. Control.
131
A
bs
or
ba
nc
e 
A
bs
or
ba
nc
e
Figure 6: Standard Curves for Human Adiponectin ELISA
Adiponectin (ng/ml)
Adiponectin (ng/ml)
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Table 2: Baseline Characteristics for Control (AGA) and Small (SGA)
groups (n (%) and Median[IQR])
S G A  (n=23) A G A  (n=23) p-value
Age (yrs) 31 [27-36] 34 [32-37] 0.146
Father’s Age (yrs) 32 [27-37] 34 [29-38] 0.507
Nulliparous 15 (65%) 14(61%) 0.763
Caucasian 19 (82%) 2 1  (91%) 0.386
Family History of IHD 2 (9%) 0  (0 %) 0.153
Booking Weight (kg) 58 [54-67] 61.7 [59-72] 0.099
Height (m) 1.60 [1.55-1.65] 1.64 [1.6-1.67] 0.054
BMI (kg/m2) 23.2 [20.4-25.5] 23.1 [20.8-26.4] 0.750
Systolic BP at 30wks (mmHg) 118 [110-123] 1 2 0  [1 1 0 -1 2 2 ] 0.765
Diastolic BP at 30wks (mmHg) 70 [68-79] 70 [60-70] 0.052
Pregnancy induced 
hypertension / Preeclampsia
3 (13%) 2 (9%) 0.639
Abnormal umbilical artery 
doppler ultrasound
4 (17%) 0  (0 %) 0.038
Abbreviations; IHD: ischaemic heart disease, BMI: body mass index, BP: blood 
pressure
Table  3: Delivery details
AGA (n=23) SGA (n=23) P-value
Birth weight (kg) 3.6 [3.17-3.85] 2.34 [2.13-2.65] -
Birth weight centile 58 [34-76] 2 [0.5-3.5] -
Gestation (days) 278 [270-286] 271 [260-278] 0.023
Caesarean section (n) 15(65%) 13 (57%) 0.665
Male infant 15(65%) 9 (39%) 0.080
Categorical variables are presented as n (%) and continuous variables median 
[IQR]. P-values are not presented for birthweights or centiles since birthweight 
defines SGA/AGA status.
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Table 4: Results at 6  week visit, (Mcdian|IQI A)
AGA (n=23) SGA (n=23) P-value
Systolic BP (mmHg) 110 [105-117] 110 [110-117] 0.772
Diastolic BP (mmHg) 70 [70-75] 72 [65-79] 0.477
Glucose (mmol/1) 4.3 [3.95-4.5] 4 . 4  [4.15-4.65] 0.256
HbAlc (%) 5.0 [4.9-5.3] 5.2 [5.1-5.4] 0.108
Insulin (mU/1) 6.3 [5.05-7.8] 7.2 [5.75-9.35] 0.124
HOMA-IR 0.8 [0.65-0.95] 0.9 [0.7-1.2] 0.116
Cholesterol (mmol/1) 5.1 [4.5-5.4] 5.5 [4.45-5.85] 0.333
LDL (mmol/1) 1.76 [1.57-2.02] 1.63 [1.41-1.93] 0.368
HDL (mmol/1) 2.8 [2.29-3.19] 3.08 [2.24-3.51] 0.231
Triglycerides (mmol/1) 0.78 [0.66-0.91] 0.98 [0.81-1.38] 0.006
Breast feeding (n(%)) 11 (48%) 7 (30%) 0.195
Abbreviations; BP: blood pressure, HbAlc: glycosylated haemoglobin, HOMA- 
IR: homeostasis model assessment of insulin resistance, LDL: low density 
lipoprotein, HDL: low density lipoprotein.
Table  5: E P C  num ber and function, (M edian IQ R1)
A G A  (n=23) S G A  (n=23) p-value
E P C  Count
(cells in 1 2 x high power 
fields)
367
[331-415]
294
[236-338]
0.005
M igration coefficient
(fractional migration 
towards VEGF)
1.59
[1.22-1.81]
0.91
[0 .8 6 - 1 ]
<0 . 0 0 1
Adhesion
(FU, Fluorescence Units)
0.284
[0.214-0.4]
0.221
[0.179-0.296]
0 . 1 2 1
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Fig. 7: EPC Number, Migration and Adhesion
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F i g u r e  8 :  R e p r e s e n t a t i v e  i m a g e s  o f  D a y  7  C e l l s  ( L i g h t  m i c r o s c o p y  4 0 0 x )  
F i g  8 a :  C e l l s  f r o m  M o t h e r  o f  A G A  i n f a n t
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F i g u r e  9 :  E P C  m i g r a t i o n  t h r o u g h  m o d i f i e d  B o y d e n  C h a m b e r  
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Fig. 10: Relationship between birth weight and EPC number
Birthweight (Kg)
F i g .  1 1 :  R e l a t i o n s h i p  b e t w e e n  b i r t h  w e i g h t  a n d  E P C  m i g r a t i o n
Birthweight (Kg)
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, 13: Relationship between E P C  m igration and serum  triglycerides
Triglyceride (mmol/l)
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Table 6: Adiponectin, (Median[IQR])
AGA (n=23) SGA (n=23) P-value
Umbilical Cord Blood
Adiponectin
(ng/ml)
70.4 [54.2-76.6] 55.2 [47-65] 0.033
Maternal Plasma 
Adiponectin
(ng/ml)
17.7 [14.8-26] 20.7 [15.3-25.6] 0 . 8
F igu re  14: C o rd  Blood Adiponectin in A G A  and S G A  groups
AGA SGA
Group
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F i g .  1 5 :  R e l a t i o n s h i p  b e t w e e n  b i r t h  w e i g h t  a n d  u m b i l i c a l  c o r d  b l o o d  
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Method = Forward Stepwise (Conditional)
Table 7: Multivariate Analysis for Confounding Factors
T a b l e  7 a :  O m n i b u s  T e s t s  o f  M o d e l  C o e f f i c i e n t s
Chi-square df Sig.
Step 1 Step 21.662 1 . 0 0 0
Block 21.662 1 . 0 0 0
Model 21.662 1 . 0 0 0
T a b l e  7 b :  M o d e l  S n m m a r y
Step
-2 Log likelihood
Cox & Snell R  
Square
Nagelkerke R  
Square
1 29.6043 .443 .591
a. Estimation terminated at iteration number 6  because parameter 
estimates changed by less than .0 0 1 .
T a b l e  7 c :  C l a s s i f i c a t i o n  T a b l e 3
Observed Predicted
Group Percentage
Control Small Correct
Step 1 Group Control 14 4 77.8
Small 1 18 94.7
Overall Percentage 86.5
a. The cut value is .500
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Table 7d: Variables in the Equation
B S.E. Wald df Sig. Exp(B)
Step l a Migration -5.905 2.037 8.401 1 .004 .003
Constant 6.942 2.258 9.456 1 . 0 0 2 1035.207
a. Variable(s) entered on step 1: EPC Migration.
T a b l e  7 e :  M o d e l  i f  T e r m  R e m o v e d “
Variable
Model Log 
Likelihood
Change in -2 
Log Likelihood df
Sig. of the 
Change
Step 1 EPC
Migration
-26.692 23.779 1 . 0 0 0
a. Based on conditional parameter estimates
T a b l e  7 f :  V a r i a b l e s  n o t  i n  t h e  E q u a t i o n
Score df Sig.
Step 1 Variables Triglyceride 1.314 1 .252
Age 2.402 1 . 1 2 1
Parity 1.399 1 .237
Systolic BP .027 1 .869
Diastolic BP 3.501 1 .061
Breastfeeding 1.079 1 .299
BMI 1.013 1 .314
Glucose . 0 1 0 1 .921
1 Insulin .049 1 .825
HOMAIR . 0 2 1 1 .885
HbAlc .674 1 .412
Cholesterol .051 1 .822
HDL .298 1 .585
LDL .016 1 .899
Adiponectin .521 1 .471
1 EPC Absorbance 1.319 1 .251
EPC Count 1.632 1 . 2 0 1
1 Overall Statistics 16.419 17 .494
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Table 8: Baseline Characteristics of 3 groups (n (%) and Median[IQR])
AGA (n=23) CSGA (n=18) IUGR (n=5) p-value*
Age (yrs) 34 [32-37] 33 [27-37] 24 [26-30] 0 . 6
Father’s Age (yrs) 34 [29-38] 35 [30-37] 26 [24-30] 0.338
Nulliparous 14 (61%) 12 (67%) 3 (60%) 0.83
Caucasian 2 1  (91%) 15 (83%) 4 (80%) 0.376
Family Histoiy of 
IHD
0  (0 %) 1 (6 %) 1 (2 0 %) 0.078
Booking Weight
(kg)
61.7 [59-72] 58 [54-68] 61 [57-66] 0.143
Height (m) 1.64 [1.6-1.67] 1.59 [1.55-1.63] 1.67 [1.6-1.68] 0.131
BMI (kg/m2) 23.1 [20.8-26.4] 23.5 [20.7-25.2] 21.6 [20.2-25.8] 0.728
Systolic BP at 
30wks(mmHg)
1 2 0  [1 1 0 - 1 2 2 ] 117 [110-124] 1 2 0  [116-120] 0.872
Diastolic BP at 
30wks(mmHg)
70 [60-70] 70 [66-72] 80 [77-82] 0 . 0 1 2
Pregnancy induced 
hypertension / 
Preeclampsia
2 (9%) 1 (6 %) 2 (40%) 0.291
Abnormal 
placental artery 
ultrasound doppler
0  (0 %) 2 (1 1 %) 2 (40%) 0 . 0 1 1
AGA: Appropriate for Gestational Age, CSGA: Constitutionally Small for 
Gestational Age, IUGR: Intra-Uterine Growth Restriction. *Jonckheere-Terpstra 
test
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Table 9: Delivery details of 3 groups
AGA (n=23) CSGA (n=18) IUGR (n=5) p-value*
Birth weight (kg) 3.6 [3.17-3.85] 2.45 [2.25-2.7] 2.1 [1-4.75] < 0 . 0 0 1
Birth weight centile 58 [34-76] 2  [2.02-2.16] < 1  [0 .1 -1 ] < 0 . 0 0 1
Gestation (days) 278 [270-286] 272 [265-280] 260 [257-262] 0 . 0 0 7
Caesarean section (n) 15 (65%) 13 (87%) 3 (60%) 0.234
Male infant 15(65%) 6  (33%) 3 (60%) 0.165
Categorical variables are presented as n (%) and continuous variables median 
[IQR] *Jonckheere-Terpstratest
T a b l e  1 0 :  R e s u l t s  a t  6  w e e k  v i s i t ,  ( M e d i a n [ I Q R ] )
AGA (n=23) CSGA (n=18) IUGR (n=5) p-value*
Systolic BP (mmHg) 110 [105-117] 110[110-116] 113 [110-130] 0.624
Diastolic BP (mmHg) 70 [70-75] 70 [65-77] 80 [76-84] 0.263
Glucose (mmol/1) 4.3 [4.0-4.5] 4 . 4  [4.1-4.6] 4.6 [4.3-4.9] 0.169
HbAlc (%) 5.0 [4.9-5.3] 5.2 [5.1-5.4] 5.1 [5.1-5.2] 0.155
Insulin (mU/1) 6.3 [5.0-7.8] 6.9 [5.7-7.8 ] 9.0 [8.8-14.4] 0.056
HOMA-IR 0.8 [0.7-1.0] 0.9 [0.7-1.0] 1 . 2  [1 .1 -1 .8 ] 0.053
Cholesterol (mmol/1) 5.1 [4.5-5.4] 5.2 [4.4-5.6 ] 5.9 [5.8-6.4] 0.155
LDL (mmol/1) 1 . 8  [1 .6 -2 .0 ] 2.7 [2.1-3.5] 3.4 [3.2-3.8 ] 0.214
HDL (mmol/1) 2.8 [2.3-3.2] 1 . 6  [1.4-1.9] 1 . 8  [1 .4-2.0] 0.268
Triglycerides (mmol/1) 0 . 8  [0.7-0.9] 0.9[0.8-1.2] 1 . 6  [1 .2 -1 .8 ] 0 . 0 0 1
Breast feeding (n(%)) 11 (48%) 6  (67%) 1 (2 0 %) 0.195
Abbreviations; BP: blood pressure, HbAlc: glycosylated haemoglobin, HOMA- 
IR: homeostasis model assessment of insulin resistance, LDL: low density 
lipoprotein, HDL: low density lipoprotein. *Jonckheere-Terpstra test
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Table 11: EPC number and function, (Median |ÏQR|)
A G A  (n=23) C S G A  (n=18) IU G R  (n=5) p-value*
E P C  Count
(cells in 1 2 x high 
power fields)
367
[331-415]
316
[244-349]
276
[206-297]
0.003
M igration coefficient
(fractional migration 
towards VEGF)
1.59
[1.22-1.81]
0.90
[0.85-1.0]
0.91
[0.88-0.99]
<0.001
Adhesion
(FU, Fluorescence 
Units)
0.284
[0.214-0.4]
0.228
[0.171-0.336]
0.213
[0.209-0.281]
0.146
*Jonckheere-Terpstra test
Table  12: Adiponectin, (M ed ian [IQ R J)
AGA (n=23) CSGA (n=18) IUGR (n=5) p-value*
Umbilical Cord Blood
Adiponectin
(ng/ml)
70.4
[54.2-76.6]
53.8
[45.3-65.0]
62.9
[59.6-66.1]
0.099
Maternal Plasma
Adiponectin
(ng/ml)
17.7
[14.8-26]
2 0 . 8
[15.6-25.8]
20.7
[15.3-21.9]
0.899
*Jonckheere-Terpstra test
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